# AUTHOR INDEX


Abdel-Rahman SZ, 1110
Abdul-Karim FW, 1147
Abeloff MD, 309
Abraham J, 649
Abrams J, 662
Achilles E, 1075
Achilles E, 208, 382
Adams J, 96
Adams MA, 1879
Adatto P, 1553
Adjei AA, 1062
Agresti R, 630
Aguilera N, 148
Agus V, 1347
Ahmad A, 1724
Aikin AA, 1401
Akai H, 214
Akutsu N, 745
Alaoui-Jamali MA, 745
Albanell J, 1830
Albanes D, 937
Alberg AJ, 768
Albert PS, 710, 1401, 1799
Albertsen PC, 388, 1822, 1864
Alessandri G, 1843
Alexander H, 1014
Ali I, 39
Allen NE, 649
Allred EN, 1075
Aloyz R, 1473
Alper O, 1375
Amos CI, 1106
An Q, 45
Anastasopoulou A, 22
Anderson BO, 1624
Anderson KE, 1575, 378
Anderson MM, 1624
Anderson S, 112
Andersson H, 324
Andriani F, 1314
Andrulis IL, 152, 700
Angarano G, 154
Angeloni A, 560
Anton-Culver H, 717, 651
Aozasa K, 1739
Apple RJ, 315
Arcediano A, 31
Ariad S, 194
Arias RD, 1624
Armitage JO, 1204
Aro J, 552
Aronson N, 1204
Asal N, 427
Asero S, 630
Ashton D, 1872
Assaad SI, 1806
Atkin W, 798
Atkins CD, 398
Atkinson E, 1293
Au J, 597, 1575
Auersperg N, 762
Auvinen A, 552
Ayanian JZ, 501
Aziz RA, 990

Bach PB, 850
Bachenheimer L, 649
Badalament RA, 597
Bader S, 691
Badwe RA, 320
Baer D, 710
Baines CJ, 396
Baldomero H, 949
Balis FM, 1401
Ballard-Barbash R, 1704
Bane BL, 427
Barany F, 858
Barbierato M, 154
Barentsz JO, 1095, 1754
Barlow WE, 447, 754
Barrett J, 1171
Barry MJ, 1822
Bartolazzi A, 1348
Bartsch H, 1652
Basche M, 64
Baselga J, 1830
Bast RC, 1437
Bastien Y, 745
Bauer DC, 930
Bauman DE, 876
Baumann B, 463
Baxter SW, 557
Baylin SB, 664
Baz D, 1419
Beecken WC, 382, 1075
Beex L, 1095
Begg CB, 850
Bell D, 1698
Bello V, 1473
Benbrook DM, 516
Benedict WF, 1465
Benharroch D, 194
Benlimame N, 745
Benner SE, 605
Bennett CL, 1204
Bennett T, 1375
Benson JR, 1419, 1493
Berg RW, 1541
Bergh J, 128
Bergkvist L, 525
Bergmann-Leitner ES, 1375
Berkowitz GS, 768
Berkowitz RS, 1458
Berlin K, 516
Bernacki RJ, 1234
Berne B, 128
Bernstein L, 705
Berrino F, 1088
Berry DA, 1188
Bertone ER, 942
Berumen J, 1325
Best J, 1267
Beyer J, 1733
Bhat K, 1103
Bi W, 427
Biggar RJ, 1569
Bignami M, 1534
Bijwaard K, 148
Birrer MJ, 1122
Black MJ, 745
Black WC, 322
Bladstrom A, 323
Blagosklonny MV, 239
Blaser MJ, 226, 937
Bliss HA, 1268
Bliss RL, 1575, 378
Blomqvist C, 153
Blot WJ, 1405
Boer R, 1153
Boetes C, 1095, 1754
Bofill JS, 1419
Boice JD, 121, 203, 877, 952
Bokemeyer C, 1733
Bombardieri E, 630
Bondy ML, 1553
Bonner R, 427
Boreham R, 134
Borg A, 319, 1215
Borrell TJ, 1246
Borresen-Dale A, 121
Bos R, 309, 1175
Bosch X, 1348
Boshoff C, 194
Bostrom A, 128
Botvin GJ, 1267
Bourboulia D, 194
Bowen PE, 1872
Bowersox J, 979
Boynton K, 858
Bradlow H, 554
Brasher P, 903
Bratti C, 315
Bravo JC, 559
Bravo LE, 559
Breen N, 1704
Breton J, 300
Brodin B, 1348
Broman KW, 1698
Bromley CM, 315
Bromley RL, 315
Bron D, 22
Brondum-Nielsen K, 121
Brown ED, 710
Brown K, 1267
Brown L, 559
Brown ML, 447, 1704
Broxson A, 1081
Bruner JM, 1553
Bryant A, 134
Bryant J, 684
Bubendorf L, 1141
Bucher C, 1141
Buckner JC, 1246
Buetow KH, 315
Buist D, 447
Bull SB, 700
Bult P, 1095
Bunn PA, 1385
Burbee DG, 691
Buring JE, 488
Burk RD, 315
Burny A, 1843
Burzykowski T, 399
Buxbaum S, 635, 1573
Buyse M, 399
Byers T, 64
Byrne C, 358

Caan BJ, 1799
Cabot MC, 347
Cabral FR, 1234
Calabro ML, 154
Calle EE, 720
Camerini T, 240
Cameron R, 1267
Campbell IG, 557
Campbell WS, 710
Cantelli-Forti G, 1110
Cao J, 1159
Capobianchi A, 560
Caporaso N, 157
Carbone A, 22
Carde P, 22
Carlin A, 583
Carlson RW, 399
Carlton PS, 990
Carmella SG, 378
Carrassi A, 1175
Carter D, 1811
Caruso A, 1843
Cascinelli N, 630
Castelao J, 538
Cauley JA, 930
Cazzaniga M, 1624
Chajes V, 1088
Chakravarti A, 635, 1573
Chan JM, 1330
Chandler D, 710
Chang L, 783
Chang Y, 1392
Chang-Claude J, 1657
Chao J, 1458
Chappuis PO, 152, 1754
Chaudhuri B, 436
Chen C, 1644
Chen J, 1392
Chen L, 1872
Chen T, 400
Chen Z, 1473
Cheng L, 1147
Cheng S, 1644
Cheng S, 45
Chew KL, 1791
Chieco-Bianchi L, 154
Chin J, 597
Chobanyan NS, 1575
Christiani DC, 645, 1818
Christianson RE, 1133
Christodoulopoulos G, 1473
Christov K, 1103
Chu KC, 277
Chu W, 148
Chua S, 783
Chute JP, 400
Ciatto S, 876
Cirillo PM, 1133
Clark GM, 65
Clark JW, 139
Clark RR, 1624
Claus EB, 1811
Clayton RR, 1270
Cleary PD, 139
Clevidence BA, 710
Cnattingius S, 60
Cohn BA, 1133
Colditz GA, 358, 942, 1563
Collier RJ, 876
Collman G, 768
Colussi C, 1534
Contessa JN, 921
Conti E, 319
Cook E, 139
Cook LS, 319
Cook RJ, 534
Cooksley CD, 1264
Coradini D, 1175
Corle DK, 710
Correa P, 559
Cortes-Funes H, 31
Costa A, 1175
Costa A, 240
Costantino JP, 16, 334, 1615
Couch FJ, 1633
Couture J, 583
Cozen W, 705
Cramer DW, 319, 1458
Cramer LD, 850
Crawford E, 219, 1174
Crescenzi M, 1534
Crippa F, 630
Crocetti E, 876
Crowder J, 538
Crystal RG, 1858
Cummings SR, 930
Cuthbert AP, 865
Cuzick J, 733, 1348
Czerniak B, 413

D'Alessio P, 1843
D'Allessio M, 858
D'Amato RJ, 208

# AUTHOR INDEX


Abdel-Rahman SZ, 1110
Abdul-Karim FW, 1147
Abeloff MD, 309
Abraham J, 649
Abrams J, 662
Achilles E, 1075
Achilles E, 208, 382
Adams J, 96
Adams MA, 1879
Adatto P, 1553
Adjei AA, 1062
Agresti R, 630
Aguilera N, 148
Agus V, 1347
Ahmad A, 1724
Aikin AA, 1401
Akai H, 214
Akutsu N, 745
Alaoui-Jamali MA, 745
Albanell J, 1830
Albanes D, 937
Alberg AJ, 768
Albert PS, 710, 1401, 1799
Albertsen PC, 388, 1822, 1864
Alessandri G, 1843
Alexander H, 1014
Ali I, 39
Allen NE, 649
Allred EN, 1075
Aloyz R, 1473
Alper O, 1375
Amos CI, 1106
An Q, 45
Anastasopoulou A, 22
Anderson BO, 1624
Anderson KE, 1575, 378
Anderson MM, 1624
Anderson S, 112
Andersson H, 324
Andriani F, 1314
Andrulis IL, 152, 700
Angarano G, 154
Angeloni A, 560
Anton-Culver H, 717, 651
Aozasa K, 1739
Apple RJ, 315
Arcediano A, 31
Ariad S, 194
Arias RD, 1624
Armitage JO, 1204
Aro J, 552
Aronson N, 1204
Asal N, 427
Asero S, 630
Ashton D, 1872
Assaad SI, 1806
Atkin W, 798
Atkins CD, 398
Atkinson E, 1293
Au J, 597, 1575
Auersperg N, 762
Auvinen A, 552
Ayanian JZ, 501
Aziz RA, 990

Bach PB, 850
Bachenheimer L, 649
Badalament RA, 597
Bader S, 691
Badwe RA, 320
Baer D, 710
Baines CJ, 396
Baldomero H, 949
Balis FM, 1401
Ballard-Barbash R, 1704
Bane BL, 427
Barany F, 858
Barbierato M, 154
Barentsz JO, 1095, 1754
Barlow WE, 447, 754
Barrett J, 1171
Barry MJ, 1822
Bartolazzi A, 1348
Bartsch H, 1652
Basche M, 64
Baselga J, 1830
Bast RC, 1437
Bastien Y, 745
Bauer DC, 930
Bauman DE, 876
Baumann B, 463
Baxter SW, 557
Baylin SB, 664
Baz D, 1419
Beecken WC, 382, 1075
Beex L, 1095
Begg CB, 850
Bell D, 1698
Bello V, 1473
Benbrook DM, 516
Benedict WF, 1465
Benharroch D, 194
Benlimame N, 745
Benner SE, 605
Bennett CL, 1204
Bennett T, 1375
Benson JR, 1419, 1493
Berg RW, 1541
Bergh J, 128
Bergkvist L, 525
Bergmann-Leitner ES, 1375
Berkowitz GS, 768
Berkowitz RS, 1458
Berlin K, 516
Bernacki RJ, 1234
Berne B, 128
Bernstein L, 705
Berrino F, 1088
Berry DA, 1188
Bertone ER, 942
Berumen J, 1325
Best J, 1267
Beyer J, 1733
Bhat K, 1103
Bi W, 427
Biggar RJ, 1569
Bignami M, 1534
Bijwaard K, 148
Birrer MJ, 1122
Black MJ, 745
Black WC, 322
Bladstrom A, 323
Blagosklonny MV, 239
Blaser MJ, 226, 937
Bliss HA, 1268
Bliss RL, 1575, 378
Blomqvist C, 153
Blot WJ, 1405
Boer R, 1153
Boetes C, 1095, 1754
Bofill JS, 1419
Boice JD, 121, 203, 877, 952
Bokemeyer C, 1733
Bombardieri E, 630
Bondy ML, 1553
Bonner R, 427
Boreham R, 134
Borg A, 319, 1215
Borrell TJ, 1246
Borresen-Dale A, 121
Bos R, 309, 1175
Bosch X, 1348
Boshoff C, 194
Bostrom A, 128
Botvin GJ, 1267
Bourboulia D, 194
Bowen PE, 1872
Bowersox J, 979
Boynton K, 858
Bradlow H, 554
Brasher P, 903
Bratti C, 315
Bravo JC, 559
Bravo LE, 559
Breen N, 1704
Breton J, 300
Brodin B, 1348
Broman KW, 1698
Bromley CM, 315
Bromley RL, 315
Bron D, 22
Brondum-Nielsen K, 121
Brown ED, 710
Brown K, 1267
Brown L, 559
Brown ML, 447, 1704
Broxson A, 1081
Bruner JM, 1553
Bryant A, 134
Bryant J, 684
Bubendorf L, 1141
Bucher C, 1141
Buckner JC, 1246
Buetow KH, 315
Buist D, 447
Bull SB, 700
Bult P, 1095
Bunn PA, 1385
Burbee DG, 691
Buring JE, 488
Burk RD, 315
Burny A, 1843
Burzykowski T, 399
Buxbaum S, 635, 1573
Buyse M, 399
Byers T, 64
Byrne C, 358

Caan BJ, 1799
Cabot MC, 347
Cabral FR, 1234
Calabro ML, 154
Calle EE, 720
Camerini T, 240
Cameron R, 1267
Campbell IG, 557
Campbell WS, 710
Cantelli-Forti G, 1110
Cao J, 1159
Capobianchi A, 560
Caporaso N, 157
Carbone A, 22
Carde P, 22
Carlin A, 583
Carlson RW, 399
Carlton PS, 990
Carmella SG, 378
Carrassi A, 1175
Carter D, 1811
Caruso A, 1843
Cascinelli N, 630
Castelao J, 538
Cauley JA, 930
Cazzaniga M, 1624
Chajes V, 1088
Chakravarti A, 635, 1573
Chan JM, 1330
Chandler D, 710
Chang L, 783
Chang Y, 1392
Chang-Claude J, 1657
Chao J, 1458
Chappuis PO, 152, 1754
Chaudhuri B, 436
Chen C, 1644
Chen J, 1392
Chen L, 1872
Chen T, 400
Chen Z, 1473
Cheng L, 1147
Cheng S, 1644
Cheng S, 45
Chew KL, 1791
Chieco-Bianchi L, 154
Chin J, 597
Chobanyan NS, 1575
Christiani DC, 645, 1818
Christianson RE, 1133
Christodoulopoulos G, 1473
Christov K, 1103
Chu KC, 277
Chu W, 148
Chua S, 783
Chute JP, 400
Ciatto S, 876
Cirillo PM, 1133
Clark GM, 65
Clark JW, 139
Clark RR, 1624
Claus EB, 1811
Clayton RR, 1270
Cleary PD, 139
Clevidence BA, 710
Cnattingius S, 60
Cohn BA, 1133
Colditz GA, 358, 942, 1563
Collier RJ, 876
Collman G, 768
Colussi C, 1534
Contessa JN, 921
Conti E, 319
Cook E, 139
Cook LS, 319
Cook RJ, 534
Cooksley CD, 1264
Coradini D, 1175
Corle DK, 710
Correa P, 559
Cortes-Funes H, 31
Costa A, 1175
Costa A, 240
Costantino JP, 16, 334, 1615
Couch FJ, 1633
Couture J, 583
Cozen W, 705
Cramer DW, 319, 1458
Cramer LD, 850
Crawford E, 219, 1174
Crescenzi M, 1534
Crippa F, 630
Crocetti E, 876
Crowder J, 538
Crystal RG, 1858
Cummings SR, 930
Cuthbert AP, 865
Cuzick J, 733, 1348
Czerniak B, 413

D'Alessio P, 1843
D'Allessio M, 858
D'Amato RJ, 208

D'Anna R, 1843
Daidone M, 1175
Daling JR, 754, 1008, 1753
Dalkin B, 401
Damen U, 472
Danilenko M, 1224
Danks JA, 234
Darragh TM, 843
Daures J, 300
Davidovici B, 194
Davis S, 1557
Davis WS, 1704
Dawsey SM, 226
Day R, 1615
de Andrade M, 1553
de Caestecker MP, 556
de Koning HJ, 1153
de Sanjose S, 1348
De Palo G, 240
Deapen D, 705
Debieuvre D, 300
Decensi A, 486
Deffenbaugh A, 1633
della Rovere G, 1419
Demant P, 1484
Demetris A, 1652
Demicheli R, 1572
Dempsey EC, 1385
Deng J, 783
Denner L, 1314
Dent P, 921
Deschenes J, 152
Devesa SS, 678
Dewhirst MW, 1337
Diab SG, 65
Dignam J, 1420
Dignam JJ, 112, 684
Dillner J, 284
Dirsch O, 472
Donaldson SS, 618
Done SJ, 700
Dong S, 858
Dong Z, 226
Donohue JH, 1633
Dooley WC, 1624
Dorgan JF, 710
Dornfield KJ, 1512
Droz J, 1733
DuHamel KN, 810
Dube M, 151
Duncan C, 1872
Dupin N, 194

Eble JN, 1147
Eckert S, 51
Eckhardt S, 178
Edgerton M, 666
Edwards BK, 824, 1656
Eerola H, 153
Einhorn L, 1733
Eisenberger MA, 219, 1174
Eisenhofer DS, 649
Eisinger F, 158
Ekbom A, 60
El-Zein R, 1553
Eley J, 388, 1864
Elferink C, 776
Elledge RM, 65, 1624
Elmore JG, 754
Elston RC, 635, 1573
Epstein SS, 238
Erdas R, 1175
Erickson V, 96
Erlandsson G, 60
Eskandarian S, 700
Esserman LJ, 1624
Estrada RA, 1325
Ethier S, 890
Etzioni R, 1054
Euhus DM, 1624
Evans G, 716
Fabbro D, 436
Fabian CJ, 68, 1762
Fagerstrom RM, 322
Faggioni A, 560
Fan H, 1603
Fan Z, 45
Fang B, 1314
Farber JL, 1525
Farina A, 560
Favis R, 858
Fawaz LM, 1724
Feigal EG, 400, 1656
Feinberg A, 1698
Feldman AL, 1014
Feng P, 427
Feng Z, 1054
Fernandez A, 208, 382, 1075
Ferrara N, 762
Ferraris C, 630, 1660
Feskanich D, 791
Feyerabend C, 134
Fidler IJ, 1040
Fiedler M, 472
Fijneman RJ, 1484
Fiore JR, 154
Fisher B, 112, 684, 1420
Fisher ER, 112
Fisher RI, 4
Fizazi K, 1733
Flamm C, 1204
Flay BR, 1267
Fleshman J, 583
Flood A, 791
Flynn E, 382, 1075
Fojo T, 649, 1434
Folkman J, 382, 734, 1075
Follen M, 1293
Fong KM, 691
Fong L, 1525
Fontham EH, 559
Forgacs E, 691
Forrest AM, 456
Forster R, 1588
Forsyth PA, 903
Fossa SD, 1733
Foulkes WD, 152, 1754
Frame P, 1676
Franceschi S, 319, 1348
Franco EL, 1348
Frank TS, 1633
Franklin WA, 1385
Frati L, 560
Fraumeni JF, 1405
Frazer IH, 1348
Frazier ML, 1106
Frebourg T, 66
Freedman M, 51
Fretz H, 436
Freudenheim JL, 768
Friedman DL, 618
Frisch M, 1569
Frost MH, 1633
Fry W, 605
Fryzek JP, 640, 1405
Fuchs CS, 501, 942
Fuimicino S, 1534
Fukui T, 1739
Furet P, 436

Gabet A, 367
Gago-Dominguez M, 538
Gail MH, 334, 559
Gallo RC, 1843
Galvan SC, 1325
Gandara DR, 605
Ganz PA, 96, 1615, 1624
Gao B, 691
Gao T, 1159
Gao Y, 45
Gao Y, 783
Gapstur SM, 1449
Garabrant DH, 640
Garcia-Carbonero R, 31
Garcia-Carranca A, 1325
Gardner GJ, 1122
Garland J, 555
Gasperini P, 154
Gautschi O, 463
Gazdar AF, 67, 413, 691
Gaziano J, 1330
Gelmon K, 1656
Geng L, 858
Gennaro M, 630, 1660
Gentile G, 560
Gentzschein E, 783
Gerali A, 630
Gerl A, 1733
Gerner EW, 57
Gessain A, 367
Ghadirian P, 152
Ghosh L, 1872
Giffen CA, 710
Gillies SD, 382
Gilligan M, 1344
Gilliland FD, 388, 401, 1864
Giovanazzi R, 630
Giovannucci EL, 525, 791, 1330
Giri D, 1783
Glynn RJ, 488
Godward S, 878
Goetzl EJ, 762
Goffin JR, 1754
Gofton TE, 1879
Gold M, 516
Goldman DP, 238
Goldstein DS, 649
Gomez C, 31
Gonzalez EB, 1638
Gonzalez-Lira G, 1325
Goodman GE, 605
Goodman SN, 858
Gordon MS, 1204
Graeff H, 913
Graham CH, 1879
Graham FL, 472
Granath F, 60
Grant CS, 1633
Gratwohl A, 949
Gray DL, 990
Graziano SL, 605
Greco M, 630, 1660
Greenblatt RM, 843
Greenson JK, 640
Griffith TS, 998
Gromeier M, 889
Groshen SG, 1465
Grossmann ME, 1687
Gu J, 1147
Guillem JG, 583
Guillem V, 31
Guillemette C, 1411
Gupta A, 990
Guruswamy S, 516

Haber D, 1698
Hacker NF, 1375
Haffty BG, 1624
Hahnemann M, 121
Hakama M, 552
Hall J, 463
Hallmans G, 650
Hamada J, 214
Hamel N, 152
Hamilton AS, 1864
Hamilton SR, 858, 1282
Hammarstrom L, 121
Hammond S, 618
Hanabuchi S, 1775
Hankinson SE, 768, 942
Hanrahan CF, 309
Hansen H, 525
Hansen J, 1513
Hansen WB, 1267
Hanson I, 716
Harada Y, 1739
Harbeck N, 913
Harbrecht J, 597
Hardell L, 952
Harlan LC, 388, 1864
Haroon ZA, 1337
Harpole DH, 1886
Harris CC, 1652
Harris JE, 951
Harris TL, 234
Harro CD, 284
Hart A, 1484
Hartge P, 319, 678
Hartman TJ, 710
Hartmann JT, 1733
Hartmann LC, 1297, 1633
Hasegawa A, 1775
Haslam K, 1348
Hassan R, 516
Hasselblad V, 1204
Hawkins NJ, 1307
Hawkins WT, 921
Hawthorne M, 1103
Hayes DF, 80
Hayes RB, 1021
Hayward GS, 194
Heath CW, 720
Hecht SS, 378, 1575
Hecker H, 1733
Helzlsouer KJ, 768
Hemminki K, 323, 651
Hemstreet GP, 427, 1492
Henderson MA, 234
Hendriks J, 1095
Henning G, 1588
Henrique R, 1747
Herbert B, 39
Herman JG, 664
Herrero R, 315
Hewit TH, 921
Hewitt S, 1014
Hibi K, 858
Hidalgo M, 178
Hildesheim A, 284, 315
Hirsch FR, 1385
Hittelman WN, 1081, 1257
Hjalgrim H, 1569
Hockel M, 266
Hocking B, 877
Hodgson DC, 501
Hoedemaeker R, 1153
Hoekstra O, 1659
Hoffman R, 388, 401, 1864
Hoffmann RG, 1344
Holford TR, 768
Holli K, 153
Holly EA, 843
Holmberg L, 525
Hong T, 1392
Hong W, 605, 1081, 1257
Hong Y, 645
Hoover RN, 545, 1119
Hopper JL, 234
Horikawa I, 1171
Hornedo J, 31
Horwich A, 1733
Hosokawa M, 214

Howe HL, 824, 1656
Hrushesky W, 1572
Hsing AW, 783
Hu Y, 762
Huang H, 1687
Huang H, 768
Hubscher T, 1141
Huff J, 239
Hung DT, 1624
Hunt WC, 388
Hunter DJ, 358, 768, 942, 1563
Huntley BK, 1246
Hurst RE, 427
Hussain S, 1652
Hwang ST, 1638
Ibarguen H, 1081
Iber FL, 1799
Im M, 645
Ingvar C, 324
Inoue H, 1739
Irie RF, 1159
Ishak KG, 1652
Ittmann M, 1783
Iturria N, 1246
Ivey R, 516
Iwamoto K, 768

Jaffe RB, 762
Jager GJ, 1095
Jaiswal AK, 1166
James C, 1246
James VJ, 873
Jang SJ, 1257
Janicke F, 913
Jarvis MJ, 134
Javaherian K, 382
Jay N, 843
Jayawardena TM, 1698
Jemal A, 277, 678
Jen J, 858
Jenkins RB, 1246, 1633
Jernstrom H, 554
Jeronimo C, 1747
Joffe S, 139
Johannsson OT, 1215
Johansen C, 203, 877, 952
Johnson BE, 254, 400
Johnson C, 858
Johnson KC, 719
Johnson WD, 559
Johnston RN, 903
Jones PA, 1465
Jordan V, 2, 1449
Joussen AM, 382
Judd JT, 710
Julian-Reynier C, 158
Juusela H, 552

Kaaks R, 650
Kaanders J, 1337
Kaariainen H, 121
Kagawa S, 1314
Kahn KL, 96
Kaijser M, 60
Kainu T, 153
Kallioniemi O, 153
Kannagi M, 1775
Kanter P, 1234
Kanwar JR, 1541
Kanwar RK, 1541
Kanz L, 1733
Karakis I, 194
Karp DD, 605
Karron RA, 284
Kasper S, 1314
Kass FC, 1624
Kataoka N, 558
Kato H, 1775
Kavanah M, 16
Kawachi I, 1563
Kawakita M, 998
Kaye FJ, 415, 1832
Kealey KA, 1269
Kee K, 1234
Kelley MC, 1624
Kelley MJ, 1886
Kelloff GJ, 1103
Kennedy TC, 1385
Key T, 649
Khan MA, 1652
Khan SA, 1624
Khuri FR, 605
Kikendall JW, 1799
Kilgore ML, 238
Kim H, 645
Kim HW, 605
Kimler BF, 68, 1762
King BL, 1624
King EB, 1624, 1791
Kingston R, 716
Kinnard M, 640
Kinzler KW, 858
Kisker O, 1075
Kleinerman RA, 121
Kleinman HK, 965
Kluin-Nelemans HC, 22
Kr ısel RT, 1344
Kobayashi Y, 214
Kondo M, 691
Kong S, 1106
Konishi Y, 214
Kononen J, 1141
Kopelovich L, 39, 1103
Kowdley KV, 1652
Koya Y, 1775
Kramer D, 865
Krissansen GW, 1541
Kristoffersson U, 1215
Krogh V, 1088
Kruger Kjaer S, 1348
Kubo A, 415
Kuerer HM, 1624
Kuller LH, 930
Kumar S, 555
Kurie JM, 67, 1081, 1257
Kuter I, 1806

La Vecchia C, 319
Laden F, 768, 1563
Lal A, 13371
Lally CA, 720
Lam S, 67
Lammering G, 921
Lamy A, 66
Lance P, 1799
Land CE, 1021
Lanza E, 1799
Larsson O, 1348
Latif F, 691
Lawrence TS, 890, 1512
Lazarus P, 1411
Lazcano-Ponce E, 1325
Le C, 378, 1575
Le Buanec H, 1843
Le Chevalier T, 300
Leclercq I, 367
Lee CW, 1656
Lee J, 605, 1081, 1257
Lee JS, 1081, 1257
Lee K, 645
Lee MM, 1791
Lee P, 903
Lee Y, 1392
Leech SH, 463
Legator MS, 1110
Legler JM, 401
Leheji R, 1095
Lemarie E, 300
Leopold PL, 1858
Lerman MI, 691
Lerner SP, 597
Leroy A, 367
Levin B, 858, 1106, 1264
Levin VA, 1553
Lewis S, 635, 1573
Li C, 45
Li C, 555
Li CI, 1008, 1753
Li D, 559
Li G, 427
Li S, 1886
Li X, 1314
Liang G, 1465
Liau G, 965
Liaw Y, 1644
Libutti S, 1014
Licht J, 1659
Lichtenstein P, 60
Lichtin AE, 1204
Lichy J, 148
Lightfoot S, 516
Limburg PJ, 226, 937
Lin P, 921
Lin Q, 315
Lin R, 745
Lin S, 1644
Lindman H, 128
Linehan WM, 649
Ling I, 1569
Lippman ME, 51, 80
Lippman SM, 605, 1264
Lipworth L, 1405
Litvak DA, 347
Liu D, 1081, 1257
Liu G, 1818
Liu L, 705
Ljung B, 930, 1624
Ljungman M, 82
Lo K, 382
Lo SB, 51
Loman N, 1215
Long DJ, 1166
Lonnqvist T, 121
Lopes C, 1747
Lopez-Brea M, 31
Lorang D, 1014
Lotan R, 605
Love SM, 1624
Lowy DR, 284, 1348
Lu Y, 1852
Lubbert M, 1465
Lumbreras C, 31
Lynch HT, 1479, 1586
Lynch J, 1586
Lynch PM, 1106
Lynch TJ, 1818

Ma J, 1330
Maattanen L, 552
MacMillen M, 635, 1573
Macri' C, 1534
Maes B, 22
Magrigal-De La Campa A, 1325
Maher E, 716
Major PP, 534
Maki W, 1638
Malcom GT, 559
Malone KE, 1008, 1753
Mann SL, 1269
Mansky LM, 336
Mansukhani A, 1783
Mao L, 1257
Marcelli M, 1314
Marchbanks PA, 319
Marcus PM, 322
Marek PM, 1269
Mariani L, 240
Mark S, 226
Markowitz SD, 635, 1573
Marks RS, 605
Marrogi A, 1652
Martin JP, 798
Martin T, 234
Martínez ME, 1764
Martino P, 560
Mascarenhas D, 1852
Massuger LG, 1095
Mast, 284
Masters JR, 1574
Masuda T, 1775
Matthews NE, 1879
Matusik RJ, 1314
Maxwell LR, 1879
Mayo MS, 68
Mayordomo JI, 31
McCall S, 148
McCann J, 878
McCormack GW, 1350
McDonnell S, 1633
McDonnell TJ, 208
McKinlay MR, 234
McLaren CE, 57
McLaughlin JK, 203, 877, 952, 1405
McPhaul MJ, 1314
McPherson RA, 1714
Meadows AT, 618
Mehta RG, 1103
Mehta RR, 1103
Meijer C, 865, 1348
Meijer S, 1659
Meisner C, 913
Melbye M, 1569
Menard S, 240
Menezes J, 1724
Mera R, 559
Mertens AC, 618
Metayer J, 66
Meyer P, 873
Meyskens FL, 57, 1293
Mezzelani A, 1347
Michael H, 1147
Micheli A, 630, 1088
Michels KB, 525, 791
Miedema B, 583
Mihatsch MJ, 1141
Miike R, 1791
Mikkelson R, 921
Milchgrub S, 691
Mild K, 952
Miles BJ, 597
Miller AB, 396
Miller DP, 1818
Miller YE, 1385
Milleron B, 300
Millikan RC, 156
Mills GB, 762, 1437
Minna JD, 67, 691
Mirchandani D, 1420
Mirick DK, 1557
Moatti J, 158
Moch H, 1141
Mohr G, 1473
Moinpour CM, 219, 1174
Mok SC, 1458
Molenberghs G, 399
Moller T, 324
Mommers E, 309
Montella M, 319
Montgomery GH, 810
Montie JE, 572
Moon C, 1257

Mor G, 1714
Morice RC, 1081, 1257
Moriuchi T, 214
Moro D, 300
Morris DG, 903
Morris J, 1264
Morrow M, 1449
Morse MA, 990
Mortreux F, 367
Moseley JM, 234
Moysich KB, 768
Muggia FM, 1420
Muller L, 436
Muney AM, 480
Munoz N, 1348
Muraro R, 560
Murphy BR, 284
Murphy JR, 1385
Murphy L, 378
Murphy M, 319
Musiani P, 1534
Musson H, 22
Muti P, 1088
Muto MG, 1458

Naftolin F, 1714
Nair J, 1652
Nakae D, 214
Nakata D, 214
Nakayama M, 1739
Nakayama T, 320
Nan B, 1314
Narod SA, 151, 396, 554
Nasca PC, 319
Nattinger AB, 1344
Neglia JP, 618
Negri E, 319
Nelson H, 583
Nelson PS, 1822
Nelson RL, 790
Nelson W, 1297
Nelson WG, 1747
Nersesyan AK, 1492, 1575
Ness RB, 319
Neuhaus J, 1791
Nevanlinna H, 153
Newbold RF, 865
Newschaffer CJ, 398
Nguyen C, 1465
Nguyen TT, 1465
Nguyen VT, 1525
Nichols CR, 1733
Niemierko A, 1806
Niemitz EL, 1698
Nines R, 990
Nishikawa S, 903
Nishimura K, 1739
Nocito A, 1141
Nogueria JM, 1419
Noller KL, 545
Nonomura N, 1739
Noordijk EM, 22
Novak RF, 776
Nyren O, 1405

O'Fallon JR, 1246
O'Gorman J, 51
O'Meara ES, 754
O'Neal E, 640
O'Reilly T, 436
O'Shaughnessy J, 1624
Odermatt B, 463
Ohashi T, 1775
Ohl L, 1588
Ojima I, 1234
Okada F, 214
Okawara G, 605
Okby N, 1652
Okuyama A, 1739
Olechnowitz J, 635
Olie RA, 463
Oliveira J, 1747
Olsen JH, 121, 203, 877, 952
Olsson H, 324, 1215
Omenn GS, 1111
Ono Y, 1739
Ordonez RM, 1325
Ota DM, 583
Otani K, 398
Overkamp W, 865
Ozen M, 1783

Pacak K, 648
Page DL, 68, 1624
Pala V, 1088
Palefsky JM, 843
Palmarini M, 1603
Palmer JR, 545
Panasci LC, 1473
Pang Y, 284
Paolini M, 1110
Paradis A, 152
Park JY, 1411
Park R, 166
Paskett ED, 1799
Passe SM, 1246
Passons CM, 39
Pastorino U, 1190
Patronas N, 1401
Paty PB, 858
Paz-Ares L, 31
Pearson M, 96
Peck K, 1392
Peel DJ, 651, 717
Penberthy L, 398
Penson DF, 1822
Pera P, 1234
Perez C, 605
Perez-Gracia J, 31
Perez-Perez G, 226, 937
Perlman EJ, 1698
Perneger TV, 1600
Persky V, 790
Peters H, 1337
Peterson AV, 1269
Petrakis N, 1791
Petrelli NJ, 583
Pezzuto JM, 1103
Phillips K, 152
Phillips RF, 1624
Phung M, 57
Piedbois P, 399
Piek E, 556
Pierotti MA, 1347
Pilotti S, 240, 1347
Pinedo HM, 309
Pinsky J, 1799
Piper M, 1204
Pirruccello S, 1479
Platzer P, 635, 1573
Plna K, 323
Poirier MC, 1652
Polednak AP, 1174
Pollak MN, 1330, 1852
Pollifrone D, 597
Pont J, 1733
Ponten F, 128
Porter PL, 152
Potosky AL, 388, 401, 1864
Potten CS, 1534
Potter JD, 1054, 1572
Poudenx M, 300
Powell SN, 1806
Prechtl A, 913
Prescott RJ, 456
Primatesta P, 134
Prindiville S, 1385
Prorok PC, 322
Prudencio J, 745
Pujol J, 300
Purdie DM, 319
Putzer BM, 472

Qiao Y, 226
Quantin X, 300
Quinn Laquer B, 1479
Quiring JN, 1624
Quoix E, 300

Rahim H, 1652
Ralston ML, 843
Randie D, 691
Rannikko S, 552
Rao JY, 427
Ratliff TL, 998
Ravenel JD, 1698
Realpe J, 559
Reardon D, 921
Redd WH, 810
Redston M, 700
Reimann KS, 1569
Reis SE, 16
Retsky M, 1572
Rewcastle N, 903
Reynolds M, 284
Rhys M, 1791
Riboli E, 650, 1088
Ries LA, 824, 1656
Riggins GJ, 1337
Risch HA, 319
Ritchey JK, 998
Rivera F, 31
Riviere A, 300
Ro JY, 1081
Robboy SJ, 545
Roberts AB, 556
Robinson C, 716
Robinson R, 284
Robison LL, 618
Roche M, 1806
Rockhill B, 358
Roden RB, 284
Rodicker F, 472
Rodrigo KA, 990
Rodriguez A, 315
Roggendorf M, 472
Romano P, 397
Ronckers CM, 1021
Roobol M, 1153
Roop DR, 1166
Roozendaal KJ, 22
Ropiquet F, 1783
Rose PG, 1656
Rosenberg HM, 824, 1656
Rosini S, 1534
Rosner BA, 942
Ross RK, 538, 705
Rossing M, 754
Rostgaard K, 1569
Roth JA, 605
Roth LM, 1147
Rothman N, 157
Rubinstein WS, 1586
Rueda A, 31
Ruhm S, 472
Ruiz B, 559

Saadatian M, 1088
Sai Y, 1818
Salmeron J, 1325
San Martin J, 51
Sandhu M, 878
Sanger WG, 1479
Sankila R, 121
Santen RJ, 1714
Sarason IG, 1269
Sardella A, 1175
Sargent DJ, 583
Sarov B, 194
Sato N, 1858
Satoh E, 1739
Sauter G, 1141
Scarpidis U, 315
Schaefer PL, 1246
Schaid DJ, 1633
Schantz SP, 1411
Schatzkin AG, 791, 1799
Scheithauer BW, 1246
Schenk M, 640
Scherer C, 472
Schernhammer ES, 1563
Schiffman MH, 293, 315, 951, 1348
Schildgen O, 472
Schiller JT, 284
Schmidt-Ullrich RK, 921
Schmit PJ, 1624
Schmitt M, 913
Schoenthaler R, 1806
Schottenfeld D, 1293
Schotzau A, 1141
Schrag D, 850
Schraml P, 1141
Schroder FH, 1153
Schwartz AG, 640
Schwesinger C, 208
Scutchfield F, 1270
Seersholm N, 121
Seger D, 447
Sehgal I, 998
Seidenfeld J, 1204
Seifter EJ, 63
Sekido Y, 691
Selbmann H, 913
Sellers TA, 1633
Selvan M, 1553
Semenza GL, 309
Senchenkov A, 347
Senger D, 903
Seregni E, 630
Sesboue R, 66
Shah KV, 951
Sharif-Askari E, 1724
Sharifi R, 1872
Sharma A, 1234
Shay JW, 39
Shen W, 1541
Sherman ME, 315
Shi Z, 903
Shibata A, 1109
Shibata T, 214
Shih J, 1392
Shike M, 1799
Shin M, 1739
Shing Y, 382
Shivakumar L, 691
Shuber A, 858
Shureiqi I, 1264
Sidransky D, 858, 1747
Sieri S, 1088
Signorello LB, 1405
Siiteri PK, 1133
Simoes-Wust A, 463
Simon R, 1141
Simon RM, 400
Simoneau AR, 57
Simons JW, 309
Simpson J, 666
Sitta DL, 1633
Skates S, 1458
Skinner J, 878
Skipper PL, 538

Slattery ML, 1799
Slavin JL, 234
Smith J, 1246
Snijders P, 865
Sobue T, 320
Soderberg CL, 1633
Soderberg S, 650
Soliman AS, 1264
Solomon D, 293, 951
Song J, 1714
Song R, 1714
Soni R, 436
Sonnenschein C, 1673
Soria J, 1257
Soto A, 1673
Speizer FE, 942, 1563
Spiegelman D, 358
Spratt JS, 480
Srivastava S, 1437
St. Croix B, 1337
Stacewicz-Sapuntzaki M, 1872
Stahel RA, 463
Stampfer MJ, 1330
Stanbridge EJ, 1159
Stanczyk FZ, 710, 783
Stanford JL, 388
Stanford JL, 1822, 1864
Starcevic SL, 776
Stattin P, 650
Steeg PS, 1364
Steele VE, 990, 1103
Steenbergen R, 865
Stefanek ME, 1297
Stenman U, 552
Stephan C, 436
Stephenson AR, 388, 1864
Stetler-Stevenson WG, 1375
Stevens RG, 1557
Stewart HJ, 456
Stiewe T, 472
Stolzenberg-Solomon RZ, 937
Stoner GD, 990
Stossel A, 1569
Stoutjesdijk MJ, 1095, 1754
Stovall M, 618, 1021
Stowe M, 1811
Strausberg RL, 1337
Strickler HD, 951
Strohsnitter WC, 545
Stromberg K, 1375
Studzinski GP, 1224
Su L, 1818
Sullivan Pepe M, 1054
Sun S, 1257
Sussman S, 1267
Swain SM, 963, 1753
Sweep C, 913
Swift M, 84
Syrjakoski K, 153
Szabo E, 1042

Tachibana I, 1246
Taghian AG, 1806
Takayama H, 1739
Takemura F, 1775
Talamini R, 319
Tamborini E, 1347
Tammela T, 552
Tan-Chiu E, 16, 112
Tangen CM, 219, 1174
Tangrea JA, 1799
Tannenbaum SR, 538
Taplin SH, 447
Tarone RE, 277, 293
Tartaglia J, 998
Taubenberger J, 148
Taylor PR, 226, 710, 937
Tee M, 762
Tejpar A, 710
Tennant B, 472
Teodorovic I, 22
Terai M, 315
Terry P, 525
Tessari J, 768
Thiberville L, 66
Thirion P, 399
Thiruvathukal CE, 1014
Thomas J, 22
Thompson IM, 219, 1174
Thomssen C, 913
Thor AD, 1120
Thornquist MD, 1054
Thun MJ, 720, 824, 1656
Tian J, 998
Tindall DJ, 1687
Tokizane TD, 1739
Tolcher A, 219, 1174
Tomasic G, 240
Tonin PN, 152
Torhorst J, 1141
Tornamira M, 31
Tornkvist M, 1348
Torrenga H, 1659
Tran P, 1724
Traverso G, 858
Tres A, 31
Tretli S, 121
Tripodis N, 1484
Troisi R, 1119
Trott DA, 865
Troyan SL, 1624
Tsao-Wei D, 1465
Tschopp S, 463
Tsujimoto Y, 1739
Tucker MA, 121, 678
Turner EM, 1014
Turyk M, 790

Udagawa T, 208, 1075
Uejima H, 1698
Ulbright TM, 1147
Ulrich CM, 1572
Untch M, 913
Usadel H, 1747

Vahteristo P, 153
Valerie KC, 921
van Breeman R, 1872
van Die LE, 1095
van Diest PJ, 309, 1175 , 1659
van Gijssel H, 1652
van Leeuwen FE, 1021
van den Berg BJ, 1133
van der Hoeven J, 1659
van der Kogel AJ, 1337
van der Kwast TH, 1153
van der Wall E, 309, 1175
Vaupel P, 266
Veith J, 1234
Venema P, 597
Verduijn PG, 1021
Verma L, 716
Veronesi U, 240, 486, 1624
Vesprini D, 554
Virmani AK, 67
Virmani AK, 691
Virtamo J, 937
Vis AN, 1153
Visco V, 560
Vogelstein B, 858
Vokes EE, 605
Vredenburg MR, 1234
Vockley CW, 1633

Wacholder SW, 315, 157
Wade JL, 1204
Wagener DK, 1704
Wagle N, 238
Waikel RL, 1166
Wain JC, 1818
Wain-Hobson S, 367
Walboomers J, 865
Wall C, 396
Walls EL, 51
Walsh GL, 1081
Walsh S, 716
Walther MM, 649
Wang G, 226
Wang J, 16
Wang J, 1714
Wang L, 1257
Wang L, 1553
Wang LI, 1818
Wang T, 745
Wang W, 427
Wang X, 1166
Wang X, 1224
Wang Z, 1473
Wang Z, 284
Wang-Gohrke S, 1657
Ward RL, 1307
Warner J, 597
Warren KE, 1401
Wartenberg D, 720
Wattel E, 367
Weeks JC, 139
Wei Q, 1106, 1553
Weigel NL, 1314
Weir L, 1656
Weisenburger DD, 1479
Weiss NS, 65, 754, 1008, 1753
Weiss R, 194
Weissfeld JL, 1799
Wells A, 717
Welsh JA, 1652
Wen W, 1658
Westeel V, 300
Westerdahl J, 324
Westhof E, 367
Whitby D, 1569
White JH, 745
White M, 691
Whiteman DC, 319
Whittemore AS, 1109
Wickerham D, 16
Wientjes M, 597, 1575
Wiesner GL, 635, 1573
Wilber K, 1141
Wilcox M, 903
Wiley HE, 1638
Willett WC, 791, 942, 1330, 1563
Williams B, 605
Willis JE, 635, 1573
Winget M, 1054
Wingo PA, 824, 1656
Winn RJ, 605
Wittliff JL, 112
Wobbes T, 1095
Wolf-Dietrich B, 208
Wolff MS, 768
Wolk AM, 525
Wolmark N, 112, 684
Wong K, 1458
Wong N, 1754
Woo B, 645
Woodhouse CL, 605
Woodruff T, 720
Woods JE, 1633
Woodson K, 1799
Woolf SH, 1204
Wrensch M, 1791
Wright AC, 39
Wright WE, 39
Wu C, 1392
Wu C, 716
Wu M, 1638
Wu Y, 226
Wyatt S, 1270

Xiao Z, 45
Xie D, 558
Xie Y, 1348
Xu Z, 1473

Yang P, 1392
Yang S, 1392
Yang S, 1644
Yang W, 903
Yang Y, 1644
Yasui Y, 618, 1054
Ye M, 378
Ye W, 1405
Yin S, 427
Ying G, 640
Yiu GK, 1458
Yoshida CK, 447
You W, 559
Young D, 597
Young S, 558
Younger C, 1147
Younger J, 1806
Yu C, 1392
Yu J, 1314
Yu M, 1644
Yu MC, 538
Yuan A, 1392
Yuan J, 538
Yubero A, 31
Yue W, 1714
Yuen J, 121
Yunes E, 1325
Yung Y, 1553

Zabarovsky E, 691
Zagonel V, 22
Zagury D, 1843
Zagury J, 1843
Zang M, 427
Zangemeister-Wittke U, 463
Zappa M, 876
Zarama G, 559
Zdzienicka MZ, 865
Zeng J, 51
Zhang J, 45
Zhang S, 1147
Zhang Z, 1714
Zhao W, 998
Zhao Y, 1852
Zheng Q, 427
Zheng T, 768
Zheng W, 558, 1658
Zheng Z, 1411
Zhenzhong M, 427
Zhong H, 309
Zhou J, 1465
Zi X, 1852
Ziegler A, 463
Ziogas A, 717
Zmuda JM, 930
Zochbauer-Muller S, 67, 691
Zong J, 1106
Zong J, 194
Zou X, 226
Zumstein-Mecker S, 436

# NEWS INDEX


**Academic research**
Are physician-scientists a vanishing breed? Apr. 4, p. 490
Salary a major factor for academic oncologists, study shows, Apr. 4, p. 491
Stat bite: Median salaries for academic and nonacademic life scientists, 2001, Nov. 7, p. 1596
**Accreditation**
Examining IRBs: Are review boards fulfilling their duties? Oct. 3, p. 1440
**Adjuvant therapy**
Bladder cancer chemotherapy trial generates more questions than it answers, July 4, p. 973
Taxane evidence inconclusive in adjuvant setting, Feb. 7, p. 168
**Adolescents**
Smoking habits of young U.S. smokers counseled about tobacco use, Jan. 17, p. 95
Stat bite: New cancer cases among adolescents in England, 1997, Apr. 18, p. 578
Stat bite: Race/ethnicity of young U.S. smokers counseled about tobacco use, Jan. 3, p. 12
U.K. charity focuses on treatment of teenagers, Apr. 18, p. 577
Virtual reality may help children undergoing chemotherapy, May 2, p. 675
*see also* **Children**
**Advertising**
Hospital marketing practices: Is it appropriate to advertise new technology? Jan. 3, p. 6
**Advocacy**
Are private dollars for research shifting diseases? Feb. 21, p. 264
Cancer advocacy evolves as it gains seats on research panels, Feb. 21, p. 257
**African-Americans**
African-Americans and prostate cancer: Why the discrepancies, Mar. 7, p. 342
**Alternative medicine,** *see* **Complementary and alternative medicine**
**Aneuploidy**
When theories collide: Experts develop different models for carcinogenesis, Jan. 17, p. 92
**Angiogenesis**
Cancer drugs in pipeline span wide spectrum, Mar. 21, p. 424
Natural compounds show antiangiogenic activity, Nov. 21, p. 1685
Preventive oncology recognizes 25 years of discoveries, Mar. 7, p. 340
**Animal models**
Biomarkers, animal models key in progress of chemoprevention, July 4, p. 975
Move over, mouse: Make way for the woodchucks, ferrets, and zebrafish, Mar. 21, p. 418
**Anthrax**
Anthrax as a cancer drug? Nov. 21, p. 1680
**Apoptosis**
Preventive oncology recognizes 25 years of discoveries, Mar. 7, p. 340
**Australia**
Australian report urges nationwide radiation therapy plan, Oct. 17, p. 1516
**B cells**
Scientists report new finding in development of B cells, Apr. 18, p. 582
**Barrett's esophagus**
Barrett's esophagus: Major issues uncertain and unsolved, May 2, p. 674
**Biomarkers**
Biomarkers, animal models key in progress of chemoprevention, July 4, p. 975
Can the long road from bench to bedside be shortened? May 16, p. 738
**Biophosphonates**
Biophosphonates may be useful in treatment of bone metastases, July 18, p. 1052
**BL22**
Targeted toxins begin to live up to early expectations, May 16, p. 736
**Bladder cancer**
Bladder cancer chemotherapy trial generates more questions than it answers, July 4, p. 973
Telomerase still 'investigational' in its application to cancer management, June 6, p. 800
**Bone cancer**
Biophosphonates may be useful in treatment of bone metastases, July 18, p. 1052
**BRCA1/2**
BRCA1: Lessons learned from the breast cancer gene, Aug. 15, p. 1200
Prophylactic oophorectomy in the genome age: Balancing new data against uncertainties, Feb. 7, p. 173
**Brain cancer**
Female cancer patients at higher risk of marital problems, Aug. 1, p. 1127
**Breast cancer**
The age of breast cancer awareness: What is the effect of media coverage, Oct. 17, p. 1520
Analysis of mammography trials renews debate on mortality reduction, Nov. 21, p. 1678
Better assays needed for hormone receptor status, experts say, Apr. 18, p. 579
BRCA1: Lessons learned from the breast cancer gene, Aug. 15, p. 1200
Cancer drugs in pipeline span wide spectrum, Mar. 21, p. 424
Demystifying statistics: Experts discuss common misunderstandings, Dec. 5, p. 1768
Despite efficacy of prophylactic mastectomy, procedure finds few enthusiasts, Mar. 7, p. 338
Female cancer patients at higher risk of marital problems, Aug. 1, p. 1127
French National Ad Hoc Committee strongly resists prophylactic mastectomy, Mar. 7, p. 339
IOM report sets policy priorities for improving breast cancer screening, Apr. 18, p. 574
LIM kinase appears critical in metastasis, but how? Jan. 17, p. 88
New guidelines endorse widespread use of hormonal therapy for breast cancer, Nov. 7, p. 1599
Stat bite: Breast cancer risk in the study of tamoxifen and raloxifene, Feb. 21, p. 263
Stat bite: Incidence rates by age at diagnosis for breast and prostate cancers, Mar. 21, p. 425
Stat bite: U.S. cancer mortality in white women by 5-year time periods, 1950–1994, June 20, p. 900
Taxane evidence inconclusive in adjuvant setting, Feb. 7, p. 168
Updated breast cancer risk disk available, Apr. 18, p. 581
**Breast lesions**
Report examines management of suspicious breast lesions, Nov. 21, p. 1683

**California**
Stat bite: Lung cancer incidence in California, 1988–1997, Sept. 19, p. 1371
**Campath**
FDA panel recommends two new cancer drugs for approval, Feb. 7, p. 175
**Canada**
Canada's marijuana regulations raise efficacy, safety issues, May 16, p. 740
Canada–U.S. mortality comparison highlights analytical pitfalls, Jan. 17, p. 89
The Canadian health care system, Aug. 15, p. 1196
Canadians push national cancer strategy, Aug. 15, p. 1195
Five key priorities of the Canadian strategy for cancer control, Aug. 15, p. 1197
Guidelines outline categories of patients eligible for marijuana, May 16, p. 741
New Montreal gene centers boost basic, clinical cancer research, Sept. 19, p. 1373
**Cancer Research Campaign**
Two British cancer charities may join forces, Sept. 5, p. 1289
**Carcinogenesis**
When theories collide: Experts develop different models for carcinogenesis, Jan. 17, p. 92
**Carcinogens**
Federal carcinogen report debuts new list of nominees, Sept. 19, p. 1372
**CCI-779**
Rapamycin's resurrection: a new way to target the cancer cell cycle, Oct. 17, p. 1517
**Celebrex**
Chemoprevention: Can industry and academia collaborate? Apr. 18, p. 575
**Cell cycle**
Beyond the Nobel Prize: Cell cycle research offers new view of cancer, Dec. 5, p. 1766
Rapamycin's resurrection: a new way to target the cancer cell cycle, Oct. 17, p. 1517
Snake venom protein paralyzes cancer cells, Feb. 21, p. 261
**Cellular telephones**
More information about cellular phones, Feb. 7, p. 172
Recent studies show cell phone use is not associated with increased cancer risk, Feb. 7, p. 170
Stat bite: Number of wireless telephone users in the United States, 1985–2000, Feb. 7, p. 171
**Center for Cancer Research**
Creation of Center for Cancer Research marks cultural shift, Aug. 1, p. 1124
**Center to Reduce Cancer Health Disparities**
Freeman sets goals for Center to Reduce Cancer Health Disparities, Mar. 21, p. 420
**Cervical cancer**
Stat bite: U.S. cancer mortality in white women by 5-year time periods, 1950–1994, June 20, p. 900
Study results help define HPV's role as diagnostic tool, Feb. 21, p. 259
Vaccines: The next step for cervical cancer prevention? Feb. 21, p. 260
**Charities**
Two British cancer charities may join forces, Sept. 5, p. 1289
U.K. charity focuses on treatment of teenagers, Apr. 18, p. 577
**Chemoprevention**
Biomarkers, animal models key in progress of chemoprevention, July 4, p. 975
Chemoprevention: Can industry and academia collaborate? Apr. 18, p. 575
Chemoprevention: What's in a name? May 16, p. 743
Preventive oncology recognizes 25 years of discoveries, Mar. 7, p. 340
**Chemotherapy**
Bladder cancer chemotherapy trial generates more questions than it answers, July 4, p. 973
End-of-life cancer care: Progress still needed, Sept. 19, p. 1368
Reimbursing cancer care: Medicare policies challenged, Nov. 7, p. 1595
Virtual reality may help children undergoing chemotherapy, May 2, p. 675
*see also* **Drug therapy**
**Children**
Post-traumatic stress disorder in childhood cancer survivors: How common is it? Feb. 21, p. 262
Stat bite: Cancer survival rates for children under age 15 years in Great Britain, Aug. 1, p. 1130
Stat bite: U.S. incidence rates for selected childhood cancers, Aug. 15, p. 1201
Virtual reality may help children undergoing chemotherapy, May 2, p. 675
*see also* **Adolescents**
**Clinical trials**
Can the long road from bench to bedside be shortened? May 16, p. 738
Clinical trial design changing as molecular targets gain popularity, Dec. 5, p. 1770
Clinical trials provision makes way into Patients' Bill of Rights, Aug. 15, p. 1194
Examining IRBs: Are review boards fulfilling their duties? Oct. 3, p. 1440
Industry-funded versus publicly funded trials: Are the standards the same? Nov. 7, p. 1590
International clinical trial recommendations released, July 18, p. 1051
New Montreal gene centers boost basic, clinical cancer research, Sept. 19, p. 1373
Stat bite: Geography of published clinical cancer research, 1996–1999, Dec. 5, p. 1772
Surgical oncology focusing on minimally invasive surgery, more randomized clinical trials, June 20, p. 897
U.S. tops list of most published clinical research, Dec. 5, p. 1772
**Colorectal cancer**
Consensus on colorectal screening still difficult to achieve, Apr. 18, p. 580
Stat bite: U.S. cancer mortality in white women by 5-year time periods, 1950–1994, June 20, p. 900
Studies move closer to genetic test to detect colon cancer, June 6, p. 802
**Colonoscopy**
Consensus on colorectal screening still difficult to achieve, Apr. 18, p. 580
**Complementary and alternative medicine**
Ethnicity may affect alternative, complementary therapy choices, Oct. 17, p. 1522
Government-industry collaborations explored for alternative medicine, Aug. 1, p. 1129
Natural compounds show antiangiogenic activity, Nov. 21, p. 1685
**Conflict of interest**
Studies prompt closer scrutiny of conflict of interest policies, June 20, p. 895

**Congress**
Dramatic changes unlikely for biomedical research with new Congress, Mar. 21, p. 423
House, Senate groups voice commitment to cancer research, Mar. 21, p. 424
**Contortrostatin**
Snake venom protein paralyzes cancer cells, Feb. 21, p. 261
**Cost**
Reimbursing cancer care: Medicare policies challenged, Nov. 7, p. 1595
Stat bite: Per capita pharmaceutical expenditures in industrialized countries, 1998, Dec. 19, p. 1839
**Cotinine**
Drop in cotinine levels signals less smoke exposure, experts say, May 2, p. 669

**Decision-making**
Shared decision-making still evolving in cancer screening, May 2, p. 672
**Dendritic cells**
Cancer vaccines: Advances give hope for future therapy, July 18, p. 1044
**Diagnosis**
Does type of health insurance affect cancer care, diagnosis? June 6, p. 807
Study results help define HPV's role as diagnostic tool, Feb. 21, p. 259
**Diet**
Preventive oncology recognizes 25 years of discoveries, Mar. 7, p. 340
**Divorce**
Female cancer patients at higher risk of marital problems, Aug. 1, p. 1127
**Drug approval**
FDA panel recommends two new cancer drugs for approval, Feb. 7, p. 175
Proposals to speed up European drug approval process questioned, Nov. 21, p. 1682
**Drug therapy**
Anthrax as a cancer drug? Nov. 21, p. 1680
Canada's marijuana regulations raise efficacy, safety issues, May 16, p. 740
Cancer drugs in pipeline span wide spectrum, Mar. 21, p. 424
Guidelines outline categories of patients eligible for marijuana, May 16, p. 741
*see also* **Chemotherapy**

**Elderly**
Cancer screening in older patients: Making decisions about age cutoffs, Aug. 15, p. 1198
**Embryonic stem cells**
Embryonic stem cell debate brings politics, ethics to the bench, Aug. 15, p. 1192
What is the promise of embryonic stem cell research? Oct. 3, p. 1445
**Endocrine treatment**, *see* **Hormonal therapy**
**End-of-life care**
End-of-life cancer care: Progress still needed, Sept. 19, p. 1368
**England**, *see* **United Kingdom**
**Esophageal cancer**
New chapter opens in Iranian research story, Jan. 17, p. 86
**Estrogen receptors**
Better assays needed for hormone receptor status, experts say, Apr. 18, p. 579
Biomarkers, animal models key in progress of chemoprevention, July 4, p. 975

**Ethics**
Americans concerned about ethics, morality of scientific research, survey shows, Dec. 19, p. 1841
Embryonic stem cell debate brings politics, ethics to the bench, Aug. 15, p. 1192
Hospital marketing practices: Is it appropriate to advertise new technology? Jan. 3, p. 6
International clinical trial recommendations released, July 18, p. 1051
When research and politics collide, advice sought from ethics panels, Dec. 19, p. 1834
**Ethnicity**, *see* **Race and ethnicity**
**Europe**
Cancer incidence trends differ between Europe, United States, Oct. 3, p. 1444
Looking abroad: Do funding imbalances affect foreign competition? Oct. 3, p. 1443
French National Ad Hoc Committee strongly resists prophylactic mastectomy, Mar. 7, p. 339
Proposals to speed up European drug approval process questioned, Nov. 21, p. 1682
Stat bite: Cancer drug approvals in Europe and the United States, 1995–2001, Nov. 21, p. 1683
Stat bite: Cancer incidence estimates in Europe and the United States, 2000, Oct. 3, p. 1445
**European Medicines Evaluation Agency**
Proposals to speed up European drug approval process questioned, Nov. 21, p. 1682

**Fatigue**
Cancer fatigue: One drug fails but more are in the pipeline, June 20, p. 892
**Fear of cancer**
News headlines feed on fear of cancer risk, experts say, Jan. 3, p. 9
**Femara**
FDA panel recommends two new cancer drugs for approval, Feb. 7, p. 175
**Flooding**
Tropical storm sets back research in Houston, Sept. 19, p. 1366
**Foreign competition**
Looking abroad: Do funding imbalances affect foreign competition? Oct. 3, p. 1443
**France**
French National Ad Hoc Committee strongly resists prophylactic mastectomy, Mar. 7, p. 339
**Frederick Cancer Research and Development Center**
Anthrax as a cancer drug? Nov. 21, p. 1680
**Funding**
Are private dollars for research shifting diseases? Feb. 21, p. 264
Biomedical research 'revolution' drives push for balanced funding, Oct. 3, p. 1442
Dramatic changes unlikely for biomedical research with new Congress, Mar. 21, p. 423
Eastern European drug makers are newest players in volatile market, Dec. 19, p. 1838
House, Senate groups voice commitment to cancer research, Mar. 21, p. 424
Industry-funded versus publicly funded trials: Are the standards the same? Nov. 7, p. 1590
Looking abroad: Do funding imbalances affect foreign competition? Oct. 3, p. 1443

**Gastroesophageal reflux disease**
Barrett's esophagus: Major issues uncertain and unsolved, May 2, p. 674

**Genetics**
BRCA1: Lessons learned from the breast cancer gene, Aug. 15, p. 1200
Comparing microarray data: What technology is needed? Aug.1, p. 1126
Draft human genome sequence yields several surprises, Apr. 4, p. 493
Microarrays have arrived: Gene expression tool matures, Apr. 4, p. 492
New gene finding may yield clues to prostate cancer complexity, Mar. 7, p. 344
New Montreal gene centers boost basic, clinical cancer research, Sept. 19, p. 1373
Platypus study answers questions about gene imprinting, Sept. 19, p. 1370
Prophylactic oophorectomy in the genome age: Balancing new data against uncertainties, Feb. 7, p. 173
Studies move closer to genetic test to detect colon cancer, June 6, p. 802
**Gleevec,** *see* **STI-571**
**Glioma**
Female cancer patients at higher risk of marital problems, Aug. 1, p. 1127
**Government**
Government-industry collaborations explored for alternative medicine, Aug. 1, p. 1129
When research and politics collide, advice sought from ethics panels, Dec. 19, p. 1834
**Great Britain,** *see* **United Kingdom**
**Guidelines**
Britain implements nationwide cancer standards, Apr. 4, p. 497
Guidelines span range of cancer treatment, Apr. 4, p. 497

**Health care system**
The Canadian health care system, Aug. 15, p. 1196
Does type of health insurance affect cancer care, diagnosis? June 6, p. 807
IOM report calls for improvements in health care system, May 2, p. 668
Stat bite: Per capita pharmaceutical expenditures in industrialized countries, 1998, Dec. 19, p. 1839
**Health disparities**
Freeman sets goals for Center to Reduce Cancer Health Disparities, Mar. 21, p. 420
**History**
What Ever Happened to ...? Looking back 10 years, July 18, p. 1049
Waldmann's birthday bash celebrates milestones in scientific history, Jan. 3, p. 14
**Hormonal therapy**
Better assays needed for hormone receptor status, experts say, Apr. 18, p. 579
New guidelines endorse widespread use of hormonal therapy for breast cancer, Nov. 7, p. 1599
**Hormone replacement therapy**
Recent studies bring risks, benefits of hormone replacement therapy under scrutiny, Sept. 5, p. 1287
**Hospice care,** *see* **End-of-life care**
**Hospitals**
Hospital marketing practices: Is it appropriate to advertise new technology? Jan. 3, p. 6
**Human papillomavirus**
Study results help define HPV's role as diagnostic tool, Feb. 21, p. 259

**Imaging**
Imaging facilities focus on small animal research, Dec. 5, p. 1773
Jellyfish protein gives new glow to tumor imaging, July 4, p. 976
New imaging institute gets mixed reviews, Feb. 21, p. 256
**Immunology**
Spontaneous regression of melanoma may offer insight into cancer immunology, July 18, p. 1047
**Immunotherapy**
Telomerase still 'investigational' in its application to cancer management, June 6, p. 800
**Immunotoxins**
Targeted toxins begin to live up to early expectations, May 16, p. 736
**Imperial Cancer Research Fund**
Two British cancer charities may join forces, Sept. 5, p. 1289
**Incidence rates**
Canada–U.S. mortality comparison highlights analytical pitfalls, Jan. 17, p. 89
Cancer incidence trends differ between Europe, United States, Oct. 3, p. 1444
International data comparisons: Caveat emptor, Jan. 17, p. 90
Lymphoma rate rise continues to baffle researchers, Apr. 4, p. 494
Overall cancer incidence, mortality rates continuing to fall, report shows, June 6, p. 809
Stat bite: Cancers with increasing incidence rates, 1992-1998, June 6, p. 806
Stat bite: Incidence rates of selected cancers in Scotland, 1997, Sept. 5, p. 1291
Stat bite: Lung cancer incidence in California, 1988–1997, Sept. 19, p. 1371
Stat bite: Non-Hodgkin's lymphoma incidence and mortality, 1973–1997, Apr. 4, p. 495
Stat bite: U.S. incidence rates for selected childhood cancers, Aug. 15, p. 1201
**Infectious agents**
Preventive oncology recognizes 25 years of discoveries, Mar. 7, p. 340
**Institute of Medicine**
IOM calls for improvements in palliative care, Aug. 1, p. 1128
IOM report calls for improvements in health care system, May 2, p. 668
IOM report sets policy priorities for improving breast cancer screening, Apr. 18, p. 574
**Institutional review boards**
Examining IRBs: Are review boards fulfilling their duties? Oct. 3, p. 1440
**Insulin-like growth factor**
Platypus study answers questions about gene imprinting, Sept. 19, p. 1370
**Insurance**
Does type of health insurance affect cancer care, diagnosis? June 6, p. 807
Experts question validity of PSA testing for life insurance policies, July 4, p. 968
**Interleukin**
Scientists report new finding in development of B cells, Apr. 18, p. 582
**International Agency for Research on Cancer**
IARC shifts priorities as research needs change, June 20, p. 893
Obesity, cancer links prompt new recommendations, June 20, p. 901
**International data**
International data comparisons: Caveat emptor, Jan. 17, p. 90
**Iran**
New chapter opens in Iranian research story, Jan. 17, p. 86

**Laparoscopy**
Surgical oncology focusing on minimally invasive surgery, more randomized clinical trials, June 20, p. 897
**Leukemia**
Stat bite: 5-year relative survival rates for lymphocytic and myeloid leukemias, July 4, p. 971
STI-571 revolution: Can the newer targeted drugs measure up? July 4, p. 970
Studies document early success of STI-571, May 2, p. 670
*see also* **Non-Hodgkin's lymphoma**
**LIM kinase**
LIM kinase appears critical in metastasis, but how? Jan. 17, p. 88
**Lumpectomy**
Surgical oncology focusing on minimally invasive surgery, more randomized clinical trials, June 20, p. 897
**Lung cancer**
Organizations seek spotlight for lung cancer awareness, Nov. 7, p. 1597
Stat bite: Estimated 2000 lung cancer incidence in males in selected countries, July 18, p. 1048
Stat bite: Lung cancer incidence in California, 1988–1997, Sept. 19, p. 1371
Stat bite: U.S. cancer mortality in white women by 5-year time periods, 1950–1994, June 20, p. 900
**Lymphangiogenesis**
Lymphangiogenesis explored as potential route for metastasis, Apr. 4, p. 498

**Mammography**
Analysis of mammography trials renews debate on mortality reduction, Nov. 21, p. 1678
Conference addresses potential flaws in peer review process, Nov. 21, p. 1679
**Marijuana**
Canada's marijuana regulations raise efficacy, safety issues, May 16, p. 740
Guidelines outline categories of patients eligible for marijuana, May 16, p. 741
Supreme Court rules against use of marijuana for medicinal purposes, June 6, p. 808
**Mastectomy, prophylactic**
Despite efficacy of prophylactic mastectomy, procedure finds few enthusiasts, Mar. 7, p. 338
French National Ad Hoc Committee strongly resists prophylactic mastectomy, Mar. 7, p. 339
**Media**
The age of breast cancer awareness: What is the effect of media coverage? Oct. 17, p. 1520
News headlines feed on fear of cancer risk, experts say, Jan. 3, p. 9
Organizations seek spotlight for lung cancer awareness, Nov. 7, p. 1597
**Medicare**
HCFA approves Medicare coverage of PET scans, Feb. 7, p. 177
Medicare coverage group assesses effectiveness of new technologies, June 6, p. 805
Reimbursing cancer care: Medicare policies challenged, Nov. 7, p. 1595
**Melanoma**
Spontaneous regression of melanoma may offer insight into cancer immunology, July 18, p. 1047
**Metastasis**
Biophosphonates may be useful in treatment of bone metastases, July 18, p. 1052
LIM kinase appears critical in metastasis, but how? Jan. 17, p. 88
Lymphangiogenesis explored as potential route for metastasis, Apr. 4, p. 498
**Microarrays**
Comparing microarray data: What technology is needed? Aug. 1, p. 1126
Microarrays have arrived: Gene expression tool matures, Apr. 4, p. 492
*see also* **Genetics**
**Molecular targets**
Clinical trial design changing as molecular targets gain popularity, Dec. 5, p. 1770
STI-571 revolution: Can the newer targeted drugs measure up? July 4, p. 970
**Monoclonal antibodies**
Cancer drugs in pipeline span wide spectrum, Mar. 21, p. 424
**Mortality**
Analysis of mammography trials renews debate on mortality reduction, Nov. 21, p. 1678
Canada–U.S. mortality comparison highlights analytical pitfalls, Jan. 17, p. 89
International data comparisons: Caveat emptor, Jan. 17, p. 90
Overall cancer incidence, mortality rates continuing to fall, report shows, June 6, p. 809
Stat bite: Average years of life lost from cancer, Mar. 7, p. 341
Stat bite: Leading causes of death among females by age group, 1998, Oct. 17, p. 1521
Stat bite: Non-Hodgkin's lymphoma incidence and mortality, 1973–1997, Apr. 4, p. 495
Stat bite: U.S. cancer mortality in white women by 5-year time periods, 1950–1994, June 20, p. 900

**Nanotechnology**
Nanotechnology getting off the ground in cancer research, Dec. 19, p. 1836
**National Academy of Sciences**
What is the promise of embryonic stem cell research? Oct. 3, p. 1445
**National Cancer Act**
NCLAC report outlines policy recommendations for updating the National Cancer Act, Nov. 7, p. 1592
**National Cancer Research Institute**
New cancer institute sets out to coordinate, promote research, May 2, p. 670
**National Institute of Biomedical Imaging and Bioengineering**
New imaging institute gets mixed reviews, Feb. 21, p. 256
**National Surgical Adjuvant Breast and Bowel Project**
Chemoprevention: What's in a name? May 16, p. 743
**National Toxicology Program**
Federal carcinogen report debuts new list of nominees, Sept. 19, p. 1372
**Nobel Prize**
Beyond the Nobel Prize: Cell cycle research offers new view of cancer, Dec. 5, p. 1766
**Non-Hodgkin's lymphoma**
Lymphoma rate rise continues to baffle researchers, Apr. 4, p. 494
Rapamycin may prevent post-transplant lymphoma, Oct. 17, p. 1519
Stat bite: Non-Hodgkin's lymphoma incidence and mortality, 1973–1997, Apr. 4, p. 495
**Novartis**
After 30 years of laboratory work, a quick approval for STI-571, July 4, p. 972
STI-571 revolution: Can the newer targeted drugs measure up? July 4, p. 970

**Obesity**
Obesity, cancer links prompt new recommendations, June 20, p. 901
**Oncologic Drugs Advisory Committee**
FDA panel recommends two new cancer drugs for approval, Feb. 7, p. 175

**Ovarian cancer**
Prophylactic oophorectomy in the genome age: Balancing new data against uncertainties, Feb. 7, p. 173

**Paclitaxel**
Taxane evidence inconclusive in adjuvant setting, Feb. 7, p. 168
What Ever Happened to …? Looking back 10 years, July 18, p. 1049
**Palliative care**
IOM calls for improvements in palliative care, Aug. 1, p. 1128
**Paroxetine**
Cancer fatigue: One drug fails but more are in the pipeline, June 20, p. 892
**Patients' Bill of Rights**
Clinical trials provision makes way into Patients' Bill of Rights, Aug. 15, p. 1194
**Paxil,** *see* **Paroxetine**
**Peer review**
Conference addresses potential flaws in peer review process, Nov. 21, p. 1679
**PET scans**
HCFA approves Medicare coverage of PET scans, Feb. 7, p. 177
Medicare coverage group assesses effectiveness of new technologies, June 6, p. 805
**Pharmaceutical industry**
Corporate partnerships aiding cancer vaccine development, July 18, p. 1045
Eastern European drug makers are newest players in volatile market, Dec. 19, p. 1838
Government-industry collaborations explored for alternative medicine, Aug. 1, p. 1129
Industry-funded versus publicly funded trials: Are the standards the same? Nov. 7, p. 1590
Studies prompt closer scrutiny of conflict of interest policies, June 20, p. 895
**Physician-scientists**
Are physician-scientists a vanishing breed? Apr. 4, p. 490
Salary a major factor for academic oncologists, study shows, Apr. 4, p. 491
**Post-traumatic stress disorder**
Post-traumatic stress disorder in childhood cancer survivors: How common is it? Feb. 21, p. 262
**Prevention**
Chemoprevention: Can industry and academia collaborate? Apr. 18, p. 575
Enrollment begins for largest-ever prostate cancer prevention trial, Aug. 1, p. 1132
Preventive oncology recognizes 25 years of discoveries, Mar. 7, p. 340
**Prostate cancer**
African-Americans and prostate cancer: Why the discrepancies, Mar. 7, p. 342
Enrollment begins for largest-ever prostate cancer prevention trial, Aug. 1, p. 1132
Experts question validity of PSA testing for life insurance policies, July 4, p. 968
New gene finding may yield clues to prostate cancer complexity, Mar. 7, p. 344
Stat bite: Incidence rates by age at diagnosis for breast and prostate cancers, Mar. 21, p. 425
**Prostate specific antigen**
Experts question validity of PSA testing for life insurance policies, July 4, p. 968
**Proteomics**
Clinical proteomics program announced, Aug. 15, p. 1203
**Psychostimulants**
Cancer fatigue: One drug fails but more are in the pipeline, June 20, p. 892
**Public figures**
Panel examines impact of public figures on cancer awareness, Jan. 3, p. 8
**Public opinion**
Americans concerned about ethics, morality of scientific research, survey shows, Dec. 19, p. 1841
Panel examines impact of public figures on cancer awareness, Jan. 3, p. 8

**Race and ethnicity**
Ethnicity may affect alternative, complementary therapy choices, Oct. 17, p. 1522
Freeman sets goals for Center to Reduce Cancer Health Disparities, Mar. 21, p. 420
Stat bite: Race/ethnicity of young U.S. smokers counseled about tobacco use, Jan. 3, p. 12
**Radiotherapy**
Australian report urges nationwide radiation therapy plan, Oct. 17, p. 1516
Radiotherapy technique tackles challenge of moving target, Mar. 21, p. 422
Robotics and more: New technologies emerge for radiotherapy, Mar. 21, p. 421
**Raloxifene**
Chemoprevention: What's in a name? May 16, p. 743
Stat bite: Breast cancer risk in the study of tamoxifen and raloxifene, Feb. 21, p. 263
**Rapamycin**
Rapamycin may prevent post-transplant lymphoma, Oct. 17, p. 1519
Rapamycin's resurrection: a new way to target the cancer cell cycle, Oct. 17, p. 1517
**Registries**
Canada–U.S. mortality comparison highlights analytical pitfalls, Jan. 17, p. 89
International data comparisons: Caveat emptor, Jan. 17, p. 90
New chapter opens in Iranian research story, Jan. 17, p. 86
SEER doubles coverage by adding registries for four states, Apr. 4, p. 500
**Reimbursement**
Shared decision-making still evolving in cancer screening, May 2, p. 672
*see also* **Funding**
**Relapse**
Telomerase still 'investigational' in its application to cancer management, June 6, p. 800
**Research**
Are physician-scientists a vanishing breed? Apr. 4, p. 490
Are private dollars for research shifting diseases? Feb. 21, p. 264
Cancer advocacy evolves as it gains seats on research panels, Feb. 21, p. 257
Can the long road from bench to bedside be shortened? May 16, p. 738
Creation of Center for Cancer Research marks cultural shift, Aug. 1, p. 1124
IARC shifts priorities as research needs change, June 20, p. 893
Imaging facilities focus on small animal research, Dec. 5, p. 1773
Nanotechnology getting off the ground in cancer research, Dec. 19, p. 1836
New Montreal gene centers boost basic, clinical cancer research, Sept. 19, p. 1373
Salary a major factor for academic oncologists, study shows, Apr. 4, p. 491

Scientists recall progress and promise of translational research, Jan. 3, p. 13
Stat bite: Geography of published clinical cancer research, 1996–1999, Dec. 5, p. 1772
Studies prompt closer scrutiny of conflict of interest policies, June 20, p. 895
U.S. tops list of most published clinical research, Dec. 5, p. 1772
Van Andel Institute brings cancer research to the heartland, June 6, p. 803

**Risk and risk factors**
Demystifying statistics: Experts discuss common misunderstandings, Dec. 5, p. 1768
Obesity, cancer links prompt new recommendations, June 20, p. 901
Prophylactic oophorectomy in the genome age: Balancing new data against uncertainties, Feb. 7, p. 173
Recent studies show cell phone use is not associated with increased cancer risk, Feb. 7, p. 170
Stat bite: Lifetime risk of being diagnosed with cancer, May 16, p. 742

**Robotics**
Robotics and more: New technologies emerge for radiotherapy, Mar. 21, p. 421

**Salaries**
Salary a major factor for academic oncologists, study shows, Apr. 4, p. 491
Stat bite: Median salaries for academic and nonacademic life scientists, 2001, Nov. 7, p. 1596

**Scotland**, *see* **United Kingdom**

**Screening**
Cancer screening in older patients: Making decisions about age cutoffs, Aug. 15, p. 1198
Consensus on colorectal screening still difficult to achieve, Apr. 18, p. 580
Preventive oncology recognizes 25 years of discoveries, Mar. 7, p. 340
Shared decision-making still evolving in cancer screening, May 2, p. 672
*see also* **Mammography**

**SELECT**
Enrollment begins for largest-ever prostate cancer prevention trial, Aug. 1, p. 1132

**Selenium**
Enrollment begins for largest-ever prostate cancer prevention trial, Aug. 1, p. 1132

**Smoking**
Drop in cotinine levels signals less smoke exposure, experts say, May 2, p. 669
Smoking habits of young U.S. smokers counseled about tobacco use, Jan. 17, p. 95
Stat bite: Expenditures for U.S. cigarette advertising and promotion, 1998, May 2, p. 671
What Ever Happened to ...? Looking back 10 years, July 18, p. 1049

**Snake venom**
Snake venom protein paralyzes cancer cells, Feb. 21, p. 261

**Solid tumor complexity**
Comparing microarray data: What technology is needed? Aug. 1, p. 1126

**Stat bites**
Average years of life lost from cancer, Mar. 7, p. 341
Breast cancer risk in the study of tamoxifen and raloxifene, Feb. 21, p. 263
Cancer drug approvals in Europe and the United States, 1995–2001, Nov. 21, p. 1683
Cancer incidence estimates in Europe and the United States, 2000, Oct. 3, p. 1445
Cancer survival rates for children under age 15 years in Great Britain, Aug. 1, p. 1130
Cancers with increasing incidence rates, 1992–1998, June 6, p. 806
Estimated 2000 lung cancer incidence in males in selected countries, July 18, p. 1048
Expenditures for U.S. cigarette advertising and promotion, 1998, May 2, p. 671
5-year relative survival rates for lymphocytic and myeloid leukemias, July 4, p. 971
Geography of published clinical cancer research, 1996–1999, Dec. 5, p. 1772
Incidence rates by age at diagnosis for breast and prostate cancers, Mar. 21, p. 425
Incidence rates of selected cancers in Scotland, 1997, Sept. 5, p. 1291
Leading causes of death among females by age group, 1998, Oct. 17, p. 1521
Lifetime risk of being diagnosed with cancer, May 16, p. 742
Lung cancer incidence in California, 1988–1997, Sept. 19, p. 1371
Median salaries for academic and nonacademic life scientists, 2001, Nov. 7, p. 1596
New cancer cases among adolescents in England, 1997, Apr. 18, p. 578
Non-Hodgkin's lymphoma incidence and mortality, 1973–1997, Apr. 4, p. 495
Number of wireless telephone users in the United States, 1985–2000, Feb. 7, p. 171
Per capita pharmaceutical expenditures in industrialized countries, 1998, Dec. 19, p. 1839
Race/ethnicity of young U.S. smokers counseled about tobacco use, Jan. 3, p. 12
Smoking habits of young U.S. smokers counseled about tobacco use, Jan. 17, p. 95
U.S. cancer mortality in white women by 5-year time periods, 1950–1994, June 20, p. 900
U.S. incidence rates for selected childhood cancers, Aug. 15, p. 1201

**Statistics**
Canada–U.S. mortality comparison highlights analytical pitfalls, Jan. 17, p. 89
Demystifying statistics: Experts discuss common misunderstandings, Dec. 5, p. 1768
International data comparisons: Caveat emptor, Jan. 17, p. 90

**Steroids**
Cancer fatigue: One drug fails but more are in the pipeline, June 20, p. 892

**STI-571**
After 30 years of laboratory work, a quick approval for STI-571, July 4, p. 972
STI-571 revolution: Can the newer targeted drugs measure up? July 4, p. 970
Studies document early success of STI-571, May 2, p. 670

**Stomach cancer**
Stat bite: U.S. cancer mortality in white women by 5-year time periods, 1950–1994, June 20, p. 900

**Sunlight**
Preventive oncology recognizes 25 years of discoveries, Mar. 7, p. 340

**Surgery**
Leaders look to bolster surgical proficiency, skills verification, June 20, p. 899
Surgical oncology focusing on minimally invasive surgery, more randomized clinical trials, June 20, p. 897

**Surveillance, Epidemiology, and End Results (SEER) program**
SEER doubles coverage by adding registries for four states, Apr. 4, p. 500
**Survival**
5-year relative survival rates for lymphocytic and myeloid leukemias, July 4, p. 971
Stat bite: Cancer survival rates for children under age 15 years in Great Britain, Aug. 1, p. 1130
**SV40**
Debate on the link between SV40 and human cancer continues, Sept. 5, p. 1284
Vaccine's history prompts years of research, Sept. 5, p. 1286

**Tamoxifen**
Chemoprevention: What's in a name? May 16, p. 743
Stat bite: Breast cancer risk in the study of tamoxifen and raloxifene, Feb. 21, p. 263
Tamoxifen side effects may be attributable to other causes, Jan. 3, p. 11
**Taxol,** *see* **Paclitaxel**
**Teenagers,** *see* **Adolescents**
**Telomerase**
Telomerase still 'investigational' in its application to cancer management, June 6, p. 800
**Texas Medical Center**
Tropical storm sets back research in Houston, Sept. 19, p. 1366
**TIMP-1**
Scientists report new finding in development of B cells, Apr. 18, p. 582
**Tobacco,** *see* **Smoking**
**Translational research**
Scientists recall progress and promise of translational research, Jan. 3, p. 13
**Transplantation**
Rapamycin may prevent post-transplant lymphoma, Oct. 17, p. 1519
**Treatment**
Britain implements nationwide cancer standards, Apr. 4, p. 497
Guidelines span range of cancer treatment, Apr. 4, p. 497
**Tumor imaging**
Jellyfish protein gives new glow to tumor imaging, July 4, p. 976

**United Kingdom**
Britain implements nationwide cancer standards, Apr. 4, p. 497
Guidelines span range of cancer treatment, Apr. 4, p. 497
New cancer institute sets out to coordinate, promote research, May 2, p. 670
Scottish health executive revamps cancer care, Sept. 5, p. 1290
Stat bite: Cancer survival rates for children under age 15 years in Great Britain, Aug. 1, p. 1130
Stat bite: Incidence rates of selected cancers in Scotland, 1997, Sept. 5, p. 1291
Stat bite: New cancer cases among adolescents in England, 1997, Apr. 18, p. 578
Two British cancer charities may join forces, Sept. 5, p. 1289
U.K. charity focuses on treatment of teenagers, Apr. 18, p. 577

**Vaccines**
Cancer vaccines: Advances give hope for future therapy, July 18, p. 1044
Corporate partnerships adding cancer vaccine development, July 18, p. 1045
Vaccine's history prompts years of research, Sept. 5, p. 1286
Vaccines: The next step for cervical cancer prevention? Feb. 21, p. 260
**Van Andel Institute**
Van Andel Institute brings cancer research to the heartland, June 6, p. 803
**Virtual reality**
Virtual reality may help children undergoing chemotherapy, May 2, p. 675
**Viruses**
Debate on the link between SV40 and human cancer continues, Sept. 5, p. 1284
**Vitamin E**
Enrollment begins for largest-ever prostate cancer prevention trial, Aug. 1, p. 1132

**Women**
Female cancer patients at higher risk of marital problems, Aug. 1, p. 1127
Stat bite: Leading causes of death among females by age group, 1998, Oct. 17, p. 1521
Stat bite: U.S. cancer mortality in white women by 5-year time periods, 1950–1994, June 20, p. 900

**Youth,** *see* **Adolescents**

# SUBJECT INDEX


**Abdominal exploration,** guidelines 2000 for colon and rectal cancer surgery, 590
**Adenomas, serrated,** colorectal cancer origin, 1282 (editorial), 1307
**Adenoviruses,** hepatocellular carcinoma, treated with adenovirus-mediated delivery of interleukin 12/B7.1 genes, 463 (woodchucks)
**Adjuvant R0 stage,** guidelines 2000 for colon and rectal cancer surgery, 585
**Adjuvant therapy**
breast cancer
ER-negative, 80 (editorial), 112, 1420 (correspondence)
lymph node-negative, 913
mastectomy and adjuvant tamoxifen, 456
NIH Consensus Development Conference, 979
colon cancer, and age, after surgery, 850
**African Americans,** prostate cancer, 219, 388, 1174 (correspondence)
**AG3340,** 184
**Age,** and colorectal cancer
adjuvant chemotherapy after surgery and, 850
patient and provider characteristics, influence on treatment and outcomes, 506
risk of second primary, 1264
**Alcohol,** breast cancer, serum hormones and alcohol association, 710
**Alopecia,** adenovirus-mediated expression of Sonic hedgehog gene on hair regrowth after chemotherapy-induced alopecia, 1858 (mice)
**Anal cancer**, prevalence and risk in women, 843
**Androgen receptors**
liver cancer, hormonal markers, and hepatitis B virus-related hepatocellular carcinoma, 1644
prostate cancer, androgen-dependent apoptosis, 1314
signaling, 1687 (review)
**Anemia, cancer therapy–induced,** epoetin versus transfusion, 1204 (review)
**Angiogenesis**
liposarcoma, regulation, 1040 (editorial), 1075 (mice)
ovarian cancer, lysophosphatidic acid, and vascular endothelial growth factor, 734 (editorial), 762
tumors, transcriptional response to hypoxia, 1337
**Angiogenic therapy,** tumor inhibition, 382 (mice)
**Animal models**
HTLV-1–associated lymphomas, 1775 (rats)
lung cancer, 1603 (review) (sheep)
**Annual Report to the Nation on the Status of Cancer (1973–1998),** 824, 1656 (correspondence)
**Antibodies,** HHV8, intrafamilial transmission, 154 (correspondence)
**Antioxidant supplements,** gastric dysplasia, chemoprevention, 559 (correspondence)
**Antisense oligonucleotides,** blocking oncogenic Ras signaling for cancer therapy, 1068
**Antitelomerase agents,** breast cancer prevention, 39
**Anxiety,** behavioral intervention to control side effects of cancer treatment, 814
**Apoptosis**
breast cancer
estrogen deprivation and, 1673 (editorial), 1714
progressive resistance to apoptosis, 776
esophageal cancer, prevention by zinc replacement, 1525 (rats)
heat shock response and molecular chaperones in oncogenesis and, 239 (correspondence)
ovarian cancer, retinoids for prevention, 486 (editorial), 516
prostate cancer, fibroblast growth factor receptor signaling and, 1783
**Arm edema**, breast cancer and, 96 (review)
**ASCUS/LSIL Triage Study**, atypical squamous cells, 293, 950 (correspondence)
**Asian Americans**, cervical cancer, HPPV16 variants and, 1325
**Aspiration cytology fine-needle,** breast cancer prediction and the Gail risk model, 68 (correspondence)
**Astrocytoma, anaplastic,** PTEN, EGFR, p53, and prognosis, 1246
**Ataxia-telangiectasia,** cancer in heterozygotes, public health burden, 84 (editorial), 121
**Australia,** breast cancer, CYP17 promoter polymorphism and, 554 (correspondence)
**Av-ARR$_2$PB-Bax,** prostate cancer, androgen-dependent apoptosis, 1314

**B7-1,** lymphoma, and immunogene therapy, 1541 (mice)
**BAT26,** colorectal cancer, detection, 798 (editorial), 858
**Batimastat,** 181
**Bax,** prostate cancer, androgen-dependent apoptosis, 1314
**BAY 12-9566,** 184
**bcl-2**
breast cancer, oligonucleotide 4625-mediated inhibition, 463
prostate cancer, angiogenic potential for overexpression, 208
**bcl-xL,** breast cancer, oligonucleotide 4625-mediated inhibition, 463
**Behavioral intervention,** cancer treatment side effects, 810 (review)
**Benzidine**
bladder cancer, risk assessment and, 427, 1492 (correspondence)
urinary cancer, urinary biomarkers and, 427
**BFRF1 protein,** breast cancer, Epstein-Barr virus and, 148, 560 (correspondence)
**Biomarkers**
bladder cancer, 413 (editorial), 427, 1492 (correspondence)
detection of cancer, 1054 (commentary)
liver cancer, hormonal markers and hepatitis B virus-related hepatocellular carcinoma, 1644
lung cancer, chemoprevention, 1042 (editorial), 1081
ovarian cancer, 1437 (editorial), 1458
**Births, multiple,** cervical cancer and, 319 (correspondence)
**Bisphosphonates**, 186
**Bladder cancer**
biomarkers, benzidine exposure, risk assessment and, 427, 1492 (correspondence)
detection by microsatellite analysis, Chinese, 45
gender, smoking, and risk, 538
intravesical therapy, 572 (editorial), 597, 1574 (correspondence)
urinary markers, 413 (editorial), 427
**BMS-275291,** 185
**Bone cancer,** metastasis, methodology for treatment evaluation, 534
**Bone Marrow Transplant Registry,** 949 (correspondence)
**Bone marrow transplantation, autologous,** non-Hodgkin's lymphoma, 4 (editorial)
**Bone mass,** breast cancer and, stage at diagnosis, 930
**Bone metastases,** breast cancer, parathyroid hormone and, 234
**Book reviews,** *Clinical Oncology,* 2nd edition, 63
**Bowel washout,** guidelines 2000 for colon and rectal cancer surgery, 590
**Brain tumors,** one-, two-, and three-dimensional measurements, 1401
**BRCA1/2**
breast cancer
Finland, 152 (correspondence)
genetic assessment service for, 158 (correspondence)

population-based studies, genetic cancer risk, 1188 (editorial), 1215
prophylactic mastectomy, 1586 (editorial), 1633
**Breast cancer**
adjuvant therapy
ER-negative, 80 (editorial), 112, 1420 (correspondence), 1661 *(erratum)*
lymph node-negative, 913
NIH Consensus Development Conference, 979
apoptosis, progressive resistance to, 776
arm edema and, 96 (review)
bone mass and, stage at diagnosis, 930
BRCA1/2
Finland, 152 (correspondence)
genetic assessment service for, 158 (correspondence)
Canadian National Breast Screening Study-2, 396 (correspondence)
clinical breast examination versus mammography, 151 (correspondence)
CYP17 promoter polymorphism and, 554 (correspondence)
1,1-dichloro-2,2-bis(*p*-chlorophenyl)ethylene and polychlorinated biphenyls and, 768
drug resistance and P-glycoprotein modulation, 1234
drug resistance, Herceptin and insulin-like growth factor, 1830 (editorial), 1852
ductal carcinoma in situ and screening patterns, 1811
ductal lavage versus nipple aspiration to detect cellular atypia, 1624
epigenetic inactivation of RASSF1A, 664 (editorial), 691
Epstein-Barr virus and, 148, 560 (correspondence)
erythrocyte membrane fatty acids and, Italy, 1088
estrogen
deprivation, apoptosis and, 1673 (editorial), 1714
exposure *in utero*, 60
receptor modulation, 2 (editorial), 1449 (review)
fenretinide to prevent second breast malignancy, 240 (correspondence)
fine-needle aspiration cytology and the Gail risk model, 68 (correspondence)
hair, diffraction pattern, 873
HER2, risk and, 557 (correspondence)
HER-2/neu amplification and expression, and herceptin response, 1120 (editorial), 1141
HIF-1 and, 309, 1175 (correspondence)
hormone replacement therapy and, 733 (editorial), 754
incidence and mortality, 1973–1998, 827
induction of atypical ductal hyperplasia, 1103 (mice)
light at night, night-shift work, and risk, 1513 (editorial), 1557, 1563
magnetic resonance imaging and mammography, 1095, 1754 (correspondence)
mammary tumor cells, oxidative DNA damage by epidermal growth factor stimulation, 214 (rats)
mastectomy
adjuvant tamoxifen and, 456
breast-conserving therapy versus, cost comparison, 447
multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families, 323 (correspondence)
nipple aspiration, 1762 (editorial), 1791
oligonucleotide 4625-mediated inhibition of bcl-2 and bcl-xL, 463
p53 mutations, 666 (editorial), 700
parathyroid hormone, bone metastasis and, 234
passive smoking and mortality, 717 (correspondence)
PET staging with FDG, 630
placenta and risk, 1119 (editorial), 1133
pneumonitis, radiotherapy and paclitaxel and, 1806
population-based studies, genetic cancer risk, 1188 (editorial), 1215
prevention chemopreventive and antitelomerase agents, 39
radiotherapy, relationship of distance from a facility and initial treatment, 1344
risk
factors and screening patterns, 1811
prediction, 1762 (editorial), 1791
prediction and implications, Gail et al. model, 334 (editorial), 358
-reduction mastectomy, 1297 (review)
tamoxifen, and contralateral cancer, 963 (editorial), 1008, 1753 (correspondence)
screening, aged 40–49, 1572 (correspondence)
serum hormones and alcohol association, 710
tamoxifen
cardiovascular effects, 16
depression and, 1615
five versus ten years, 662 (editorial), 684
lymph node-negative and, 1493 (correspondence)
risk of contralateral cancer and, 963 (editorial), 1008, 1753 (correspondence)
tumor characteristics and clinical outcome of elderly women, 64 (correspondence)
**Breast density,** raloxifene, estrogen, 51
**Breast-conserving therapy,** mastectomy versus, cost comparison, 447
**Bronchoscopy, white light,** preneoplastic lesions, laser-induced fluorescence endoscopy versus, 1385

**Canadian National Breast Screening Study-2,** 396 (correspondence)
**Canarypox viruses,** prostate cancer, activation of immunoregulatory cells with, 998 (mice)
**Carcinogen-detoxifying enzyme,** orolaryngeal cancer, tobacco carcinogen-detoxifying enzyme UGT1A7 and risk, 1411
**Carcinogenesis**
breast cancer, hypoxia-inducible factor-1α, 309, 1175 (correspondence)
liver cancer, oxidative stress and p53 mutations in the carcinogenesis or iron overload-associated hepatocellular carcinoma, 1652
lung carcinogen, tobacco metabolites in environmental smoke, nonsmoking women, 378, 1574 (correspondence)
skin cancer, DMBA sensitivity, and NQO1, 1166 (mice)
urinary cancer, urinary biomarkers and, 427
**Carnosic acid,** promotion of monocytic differentiation, 1224
**β-Carotene,** lung cancer, chemoprevention or antichemoprevention, 1110 (correspondence)
**CC chemokine receptor-7,** melanoma, and, 1588 (editorial), 1638 (mice)
**CDKN2A,** multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families, 323 (correspondence)
**Cell death,** *see* Apoptosis
**Cells**
breast cancer, cell proliferation, estrogen deprivation, apoptosis and, 1673 (editorial), 1714
leukemia/lymphoma, cellular sequences, and HTLV1 provirus during clonal expansion, 367
**Cellular telephones,** cancer risk and scientists' response, 166 (editorial), 203, 877 (correspondence), 952 (correspondence)
**Central nervous system cancer,** viruses as oncolytic agent, 889 (editorial), 903
**Ceramide,** drug resistance, 347 (review)
**Cervical cancer**
atypical squamous cells, 293, 950 (correspondence)

chemoprevention trials, 1293
HPV16 and, 252 (editorial), 315
variants in Asian Americans, 1325
HPV16-E7 oncoprotein, activation of cervical microvascular endothelial cells by, 1843
**Cervix,** microvascular endothelial cells, activation by HPV16–E7 oncoprotein, 24-3
**Checklist,** guidelines 2000 for colon and rectal cancer surgery, 591
**Chemoprevention**
breast cancer, 39 , 358
cervical cancer, clinical trials, 1293
gastric dysplasia, 559 (correspondence)
head and neck squamous cell carcinoma, EB1089, 745
lung cancer, 1042 (editorial), 1081, 1110 (correspondence)
**Chemosensitivity**
ceramide metabolism, 351
nitric oxide-mediated regulation of chemosensitivity in cancer cells, 1879
**Chemotherapy**
adenovirus-mediated expression of Sonic hedgehog gene on hair regrowth after chemotherapy-induced alopecia, 1858 (mice)
behavioral intervention to control side effects, 810 (review)
lung cancer, small-cell, 254 (editorial), 300, 399 (correspondence)
non-Hodgkin's lymphoma, 22
resistance to, 1434 (editorial)
**Children**
brain tumors, one-, two-, and three-dimensional measurements, 1401
Hutchinson Smoking Prevention Project, 1267 (correspondence)
second malignant neoplasms, five-year survivors, 618
**China**
bladder cancer detection, microsatellite analysis, 45
prostate cancer, insulin and leptin and, 783
stomach cancer, and *Helicobacter pylori*, 226
**CHVmP/BV,** non-Hodgkin's lymphoma, 22
**CINK4,** cyclin-dependent kinase 4, small molecule inhibitor, 436
**Cisplatin,** lung cancer, small-cell, 300
**Clinical oncology,** 63 (book review)
**Clinical trials**
barriers to participation, 238 (correspondence), 876 (correspondence)
informed consent, 139
**Cloning,** HTLV-1 proviruses, mutations during *in vivo* clonal expansion, 336 (editorial), 367
**Cognitive restructuring,** side effects of cancer treatment and, 813
**Cognitive/attentional distraction,** side effects of cancer treatment and, 811
**Col-3 (metastat),** 186
**Collapsin response mediator protein-1,** lung cancer, and the invasion and metastasis of cancer cells, 1364 (editorial), 1392
**Colon,** guidelines 2000 for colon and rectal cancer surgery, 585
**Colonoscopy,** cost-effectiveness, 480 (correspondence)
**Colorectal cancer**
age
adjuvant chemotherapy after surgery, 850
risk of second primary, 1264
cyclin D1 polymorphism and, 1106
diet and prevention, 790 (correspondence)
DMH-induced, 1534 (mice)
DNA-based detection, 798 (editorial), 858
drug resistance and P-glycoprotein modulation, 1234
fruit, vegetables, dietary fiber, and risk, 525
guidelines 2000 for surgery, 583
hereditary nonpolyoposis families, 651 (correspondence), 716 (correspondence)
HRT and recurrence, 1764 (editorial), 1799
milk intake, circulating levels of insulin-like growth factor-I, and risk in men, 1330
origin in hyperplastic polyps and serrated adenomas, 1282 (editorial), 1307
patient and provider characteristics, influence on treatment and outcomes, 501 (review)
screening progress over a decade, 1676 (editorial), 1704
susceptibility variants at the human COX2 locus, 635 (mice), 1572 (correspondence)
**Consensus Development Conference,** breast cancer, and adjuvant therapy, 979
**Contingency management,** side effects of cancer treatment and, 811
**Coronary heart disease,** breast cancer, tamoxifen and, 2 (editorial), 16, 1449 (review)
**Cost**
breast cancer, mastectomy versus breast-conserving therapy, cost comparison, 447
colonoscopy, cost-effectiveness, 480 (correspondence)
**COX2**, colon cancer, susceptibility variants at the human COX2 locus, 635 (mice), 1572 (correspondence)
**CpG islands,** nonpromoter, susceptibility to *de novo* methylation, 1465
**Cyclin D1**
cyclin-dependent kinase 4, small molecule inhibitor, 436
colorectal cancer and, 1106
**Cyclin-dependent kinase 4,** small molecule inhibitor, 436
**Cyclin-dependent kinase inhibitors,** retinoblastoma/p16 gene pathway and, 415 (editorial)
**Cyclophosphamide**, lung cancer, small-cell, 300
**CYP17 promoter polymorphism,** breast cancer and, 554 (correspondence)
**Cytokines,** prostate cancer, and androgen receptor signaling, 1690

**Death certificates,** prostate cancer, cause of death in, 1822
**Definitions,** guidelines 2000 for colon and rectal cancer surgery, 584
**Denmark**
cancer risk and cellular telephones, 166 (editorial), 203, 877 (correspondence), 952 (correspondence)
HHV8 prevalence, young adults, 1569
**Depression,** breast cancer, tamoxifen and, 1615
**Dexamethasone,** prostate cancer and, 1739
**1,1-Dichloro-2,2-bis(*p*-chlorophenyl)ethylene,** breast cancer and, 768
**Diet**
cancer prevention, 790 (correspondence)
colorectal cancer
fiber, and risk, 525
milk intake, circulating levels of insulin-like growth factor-I, and risk, 1330
esophageal cancer, effects of dietary *N*-(4-hydroxyphenyl) retinamide on *N*-nitrosomethylbenzylamine metabolism and esophageal tumorigenesis, 990 (rats)
prostate cancer, oxidative DNA damage in patients consuming tomato sauce-based entrees, 1872
**Diethylstilbestrol,** cancer risk in men exposed *in utero,* 545
**Difluoromethylornithine**
breast cancer prevention, 39
prostate, levels, 57
**1α,25-Dihydroxyvitamin $D_3$**
head and neck squamous cell carcinoma and, 745
promotion of monocytic differentiation, carnosic acid versus, 1224

**1,12-Dimethylbenz[*a*]anthracene,** skin cancer, DMBA sensitivity, and NQO1, 1166 (mice)
**7,12-Dimethylbenz[*a*]anthracene,** induction of atypical ductal hyperplasia, 1103 (mice)
**1,2-Dimethylhydrazine,** colorectal cancer, DMH-induced, 1534 (mice)
**Distress,** behavioral intervention to control side effects of cancer treatment, 814
**DNA**
colorectal cancer, DNA-based detection, 798 (editorial), 858
repair mechanisms, 1434 (editorial)
**Doxycycline**, 186
**Drug resistance**
ceramide metabolism, 347 (review)
insulin-like growth factor-I receptor signaling, Herceptin resistance, 1830 (editorial), 1852
nitric oxide-mediated regulation of chemosensitivity in cancer cells, 1879
**Ductal lavage,** versus nipple aspiration to detect cellular atypia, 1624
**Dysarthria,** irinotecan-induced, 1419 (correspondence)

**E7 oncoprotein**, activation of cervical microvascular endothelial cells by HPV16-E7 oncoprotein, 24-3
**EB1089,** head and neck squamous cell carcinoma and, 745
**Edema,** breast cancer and arm edema, 96 (review)
**EGFR,** astrocytoma and glioblastoma, prognosis, 1246
**Emotive imagery,** side effects of cancer treatment and, 812
**En bloc resection,** guidelines 2000 for colon and rectal cancer surgery, 589
**Endoscopy,** laser-induced fluorescence, preneoplastic lesions, white-light bronchoscopy, versus, 1385
**Epidemiology**
ataxia-telangiectasia heterozygotes and cancer, 84 (editorial), 121
cellular telephones and cancer, Denmark, 166 (editorial), 203, 877 (correspondence), 952 (correspondence)
genetic variants and cancer, 156 (correspondence)
Kaposi's sarcoma-associated herpesvirus, seroepidemiology and molecular epidemiology among Jews in Israel, 194
**Epidermal growth factor,** mammary tumor cells, oxidative DNA damage, 214 (rats; cells)
**Epidermal growth factor receptor**
ionizing radiation and, 890 (editorial), 921
ovarian cancer, epidermal growth factor receptor signaling, and invasive phenotype, 1375
**4′-Epidoxorubicin,** lung cancer, small-cell, 300
**Epithelial tumor cell lines,** homologous recombinational repair, melphalan resistance and, 1473
**Epoetin,** cancer therapy–induced anemia, versus transfusion, 1204 (review)
**Epstein-Barr virus**
breast cancer and, 148, 560 (correspondence)
interleukin-15 and, 1724
***Errata***
"Cancer Mortality After Nasopharyngeal Radium Irradiation in The Netherlands: a Cohort Study" by Ronckers et al. [J Natl Cancer Inst 2001;93:1021–7 (Issue 13)], 1661
"Irinotecan-induced dysarthria" by Querci della Rovere and Benson [J Natl Cancer Inst 2001;93:1420 (Issue 18)], 1661
"Re: Re: Role of the Insulin-Like Growth factors in Cancer Development and Progression" by Collier and Bauman [J Natl Cancer Inst 2001;93:876 (Issue 11)], 1577
"Role of Breast Reconstructive Surgery in Physical and Emotional Outcomes among Breast Cancer Survivors" by Rowland et al. [J Natl Cancer Inst 2000;92:1422–9 (Issue 17)], 68
**Erythrocyte membrane fatty acids,** breast cancer and, Italy, 1088
**Esophageal cancer**
effects of dietary *N*-(4-hydroxyphenyl)retinamide on *N*-nitroso-methylbenzylamine metabolism and esophageal tumorigenesis, 990 (rats)
incidence and mortality, 1973–1998, 830
prevention by zinc replacement, 1525 (rats)
**Estrogen**
breast cancer
deprivation, apoptosis and, 1673 (editorial), 1714
risk, *in utero* exposure, 60
breast density, 51
**Estrogen receptor modulation**, breast cancer, osteoporosis, and coronary heart disease, 1449 (review)
**Ethnicity**
colorectal cancer, patient and provider characteristics, influence on treatment and outcomes, 509
*J Natl Cancer Inst* to encourage analysis, 239 (correspondence)
prostate cancer, 388
**Etoposide**, lung cancer, small-cell, 300
**European Group for Blood and Marrow Transplantation**, 949 (correspondence)
**European Organization for Research and Treatment of Cancer Lymphoma Group,** non-Hodgkin's lymphoma, high-dose chemotherapy, 22
**European Randomized Study of Screening for Prostate Cancer**, Netherlands, 1153
**Exercise,** ovarian cancer and, 942

**Fenretinide,** breast cancer, prevention of second malignancy, 240 (correspondence)
**Fetus,** maternal genetic effects on neonatal susceptibility to oxidative damage from environmental tobacco smoke, 645
**Fibroblast growth factor receptor signaling,** prostate cancer, cell survival, 1783 (cells)
**Finland**
breast cancer, BRCA1/2 in Finland, 152 (correspondence)
prostate cancer, screening, 552
**France**, lung cancer, small-cell, treatment, 300
**Fruit,** colorectal cancer risk, 525

**Gail risk model,** breast cancer prediction, aspiration cytology fine-needle and, 68 (correspondence)
**Gastric dysplasia,** chemoprevention, 559 (correspondence)
**Gender**
bladder cancer, smoking, and risk, 538
cancer risk in men exposed to diethylstilbestrol *in utero,* 545
colorectal cancer, patient and provider characteristics, influence on treatment and outcomes, 508
*J Natl Cancer Inst* to encourage analysis, 239 (correspondence)
smoking, and cancer risk assessment, 1600
**Genetic counseling**, familial multiple myeloma, 1479
**Gene therapy**
lymphoma, B7-1 immunogene therapy, 1541(mice)
retroviral endostatin gene transfer, antiangiogenesis, 965 (editorial), 1014 (mice)
**Genetics**
adenovirus-mediated expression of Sonic hedgehog gene on hair regrowth after chemotherapy-induced alopecia, 1858 (mice)
breast cancer
epigenetic inactivation of RASSFIA, 664 (editorial), 691
genetic assessment service for, 158 (correspondence)
HER2 and risk, 557 (correspondence), 1657 (correspondence)

colorectal cancer
detection, 798 (editorial), 858
hereditary nonpolyoposis, 651 (correspondence), 716 (correspondence)
susceptibility variants at the human COX2 locus, 635 (mice), 1572 (correspondence)
hTERT, *cis*-activation by the hepatitis B virus genome, 1171
lung cancer
collapsin response mediation protein-1 and the invasion and metastasis of cancer cells, 1364 (editorial), 1392
epigenetic inactivation of RASSFIA, 664 (editorial), 691
modifiers, 1484 (mice)
non-small cell, and β-tubulin gene, 1832 (editorial), 1886
retinoic acid receptor-β gene, and methylation, 66 (correspondence)
maternal genetic effects on neonatal susceptibility to oxidative damage from environmental tobacco smoke, 645
pancreatic cancer, familial risk, 640
population-based studies in assessing genetic cancer risk, 1188 (editorial), 1215
Ras, blocking oncogenic signaling for cancer therapy, 1062 (review)
retinoblastoma
p16 gene pathway, cyclin-dependent kinase inhibitors and, 415 (editorial)
RBP1L1, binding protein-related gene encoding an antigenic epitope, 1159
synovial sarcoma, novel fusion gene, SYT-SSX4, 1347 (correspondence)
variants and cancer epidemiology, 156 (correspondence)
Wilms tumor, insulin-like growth factor-II gene and, 1698
**Genomes**, lung cancer modifiers, 1484 (mice)
**Geranylgeranyl transferase type 1 inhibitors,** blocking oncogenic Ras signaling for cancer therapy, 1070
**Germ cell tumors, extragonadal,** testicular cancer and, 1733
**Glioblastoma multiforme,** PTEN, EGFR, p53, and prognosis, 1246
**Glioma**
γ-radiation sensitivity, 1512 (editorial), 1553
viruses as oncolytic agent, 889 (editorial), 903
**Glucocorticod receptors,** prostate cancer and, 1739
**P-Glycoprotein,** colon and breast cancer, drug resistance and P-glycoprotein modulation, 1234
**Granulocyte colony-stimulating factor,** febrile neutropenia, 31
**GSTP1 methylation,** prostate cancer versus normal prostate, 1747

**Hair**
adenovirus-mediated expression of Sonic hedgehog gene on hair regrowth after chemotherapy-induced alopecia, 1858 (mice)
breast cancer, diffraction pattern, 873
**Head and neck cancer,** 1α,25-dihydroxyvitamin $D_3$ analogue EB1089 and, 745
**Heat shock response,** molecular chaperones in oncogenesis and cell death, 239 (correspondence)
***Helicobacter pylori***
gastric dysplasia, chemoprevention, 559 (correspondence)
pancreatic cancer, 937
stomach cancer, China, 226
**Hepatitis B virus**
*cis*-activation of hTERT by the hepatitis B virus genome, 1171
liver cancer, hormonal markers and, 1644
**HER2**
breast cancer
amplification and expression, and herceptin response, 1120 (editorial), 1141
insulin-like growth factor-I receptor signaling, Herceptin resistance, 1830 (editorial), 1852
risk, 557 (correspondence), 1657 (correspondence)
**Herceptin**
breast cancer
HER-2/neu amplification and expression, 1120 (editorial), 1141
resistance and insulin-like growth factor-I receptor signaling, 1830 (editorial), 1852
**Hereditary cancers**, melanoma families, multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive, 323 (correspondence)
**Herpesvirus,** Kaposi's sarcoma-associated, seroepidemiology and molecular epidemiology among Jews in Israel, 194
**Hip replacement,** risk and, Sweden, 1405
**Homologous recombinational repair**, melphalan resistance, 1473
**Hormonal markers,** liver cancer, and hepatitis B virus-related hepatocellular carcinoma, 1644
**Hormone replacement therapy**, 1449 (review)
breast cancer patients and, 733 (editorial), 754
colorectal cancer, recurrence and, 1764 (editorial), 1799
**Hospitals,** colorectal cancer, patient and provider characteristics, influence on treatment and outcomes, 502
**hTERT,** *cis*-activation by the hepatitis B virus genome, 1171
**Human herpesvirus 8**
intrafamilial transmission, 154 (correspondence)
prevalence, young adults, Denmark, 1569
**Human papillomavirus**
anal cancer, in women, 843
atypical squamous cells, 293, 950 (correspondence)
cervical cancer and, 252 (editorial), 315, 1349 (correspondence)
variants in Asian Americans, 1325
cervical microvascular endothelial cells, activation by HPV16-E7 oncoprotein, 1843
L1 VLP vaccine, 284
telomerase suppression by chromosome 6, 865
**Human T-cell leukemia virus type 1**
-associated lymphomas, rat model, 1775 (rats)
proviruses, mutations during *in vivo* clonal expansion, 336 (editorial), 367
**Human telomerase reverse transcriptase,** lung cancer, *N*-(4-hydroxyphenyl)retinamide, and in smokers' lungs, 1190 (editorial), 1257
**Hutchinson Smoking Prevention Project**, 1267 (correspondence)
***N*-(4-Hydroxyphenyl)retinamide**
esophageal cancer, effects of dietary *N*-(4-hydroxyphenyl) retinamide on *N*-nitrosomethylbenzylamine metabolism and esophageal tumorigenesis, 990 (rats)
lung cancer, and hTERT in smokers' lungs, 1190 (editorial), 1257
**Hypermethylation,** lung and breast cancers, epigenetic inactivation of RASSFIA, 664 (editorial), 691
**Hypnosis/distracting imagery,** side effects of cancer treatment and, 812
**Hypoxia**
nitric oxide-mediated regulation of chemosensitivity in cancer cells, 1879
tumors, transcriptional response to hypoxia, 1337
**Hypoxia-inducible factor-1**, breast cancer, 309, 1175 (correspondence)

**Immunogene therapy,** lymphoma, 1541 (mice)
**Immunogenicity trial**, HPV16 L1 VLP vaccine, 284
**Immunoregulatory cells**, prostate cancer, activation with canarypox viruses, 998 (mice)

**Immunotherapy,** hepatocellular carcinoma, treated with adenovirus-mediated delivery of interleukin 12/B7.1 genes, 463 (woodchucks)
***In utero* exposure,** breast cancer risk, 60
**Incidence**, 1973–1998, 824, 1656 (correspondence)
cutaneous melanoma, whites in the United States, 678
prostate cancer, Italy, 876 (correspondence)
**Individual variation,** p53 responsiveness, 82 (editorial), 128
**Informed consent,** clinical trials, 139
**Insulin,** prostate cancer and, China, 783
**Insulin-like growth factors**
breast cancer, Herceptin resistance and, 1830 (editorial), 1852
cancer development and progression, 238 (correspondence), 876 (correspondence), 1577 *(erratum)*
colorectal cancer, milk intake, circulating levels of insulin-like growth factor-I, and risk in men, 1330
Wilms tumor, insulin-like growth factor-II gene and, 1698
**Insurance,** screening progress over a decade, 1676 (editorial), 1704
**Interkeukin**
IL12, hepatocellular carcinoma, treated with adenovirus-mediated delivery of interleukin 12/B7.1 genes, 463 (woodchucks)
IL15, Epstein-Barr infection and, 1724
**Intravesical therapy**, bladder cancer, 572 (editorial), 597, 1574 (correspondence)
**Invasion suppressor gene,** lung cancer, collapsin response mediation protein-1 and the invasion and metastasis of cancer cells, 1364 (editorial), 1392
**Irinotecan (CPT-11),** dysarthria, irinotecan-induced, 1419 (correspondence)
**Iron,** liver cancer, oxidative stress and p53 mutations in the carcinogenesis or iron overload-associated hepatocellular carcinoma, 1652
**Isotretinoin,** lung cancer, non-small-cell, prevention of second primary tumors, 605
**Israel,** Kaposi's sarcoma-associated herpesvirus, seroepidemiology and molecular epidemiology among Jews, 194
**Italy**
breast cancer, erythrocyte membrane fatty acids and, 1088
prostate cancer, incidence and mortality, 876 (correspondence)

**Kaposi's sarcoma**, herpesvirus, seroepidemiology and molecular epidemiology among Jews in Israel, 194
**Ki-67,** lung cancer, chemoprevention and biomarkers, 1042 (editorial), 1081
**K-RAS,** colorectal cancer, detection, 798 (editorial), 858

**Laparoscopic colectomy,** guidelines 2000 for colon and rectal cancer surgery, 586
**Leptin,** prostate cancer and, China, 783
**Leukemia, acute myeloid,** incidence and mortality, 1973–1998, 831
**Li–Fraumeni syndrome,** breast cancer prevention, chemopreventive and antitelomerase agents, 39
**Light,** breast cancer, light at night, night-shift work, and risk, 1513 (editorial), 1557, 1563
**Liposarcoma,** angiogenesis regulation, 1040 (editorial), 1075 (mice)
**Liver cancer**
hepatocellular carcinoma, treated with adenovirus-mediated delivery of interleukin 12/B7.1 genes, 463 (woodchucks)
hormonal markers and hepatitis B virus-related hepatocellular carcinoma, 1644
incidence and mortality, 1973–1998, 830
oxidative stress and p53 mutations in the carcinogenesis or iron overload-associated hepatocellular carcinoma, 1652
**Loss of imprinting,** Wilms tumor, insulin-like growth factor-II gene and, 1698

**Lung cancer**
animal model, 1603 (review) (sheep)
β-carotene, chemoprevention, 1110 (correspondence)
carcinogens, tobacco metabolites in environmental smoke, nonsmoking women, 378, 1574 (correspondence)
chemoprevention, 1110 (correspondence)
biomarker, 1042 (editorial), 1081
collapsin response mediation protein-1 and the invasion and metastasis of cancer cells, 1364 (editorial), 1392
epigenetic inactivation of RASSF1A, 664 (editorial), 691
*N*-(4-hydroxyphenyl)retinamide, and hTERT in smokers' lungs, 1190 (editorial), 1257
incidence, 1973–1998, 830
manganese superoxide dismutase alanine-to-valine polymorphism, and risk, 1818
methylation and retinoic acid receptor-α gene, 66 (correspondence)
modifiers, 1484 (mice)
mortality, 277, 320 (correspondence), 830
non-small-cell
prevention of second primary tumors, 605
β-tubulin gene, and, 1832 (editorial), 1886
small-cell chemotherapy, 254 (editorial), 300, 399 (correspondence)
**Lycopenes,** oxidative DNA damage in patients consuming tomato sauce-based entrees, 24-7
**Lymphadenectomy,** guidelines 2000 for colon and rectal cancer surgery, 586
**Lymph nodes**
childhood cancers, staging by 2-fluoro-2-deoxy-D-glucose–positron emission tomography, 630
melanoma, CC chemokine receptor-7 and, 1588 (editorial), 1638 (mice)
**Lymphocytes,** interleukin-15 and Epstein-Barr infection, 1724
**Lymphoma**
B7-1 immunogene therapy,1541 (mice)
DMH-induced, 1534 (mice)
HTLV-1–associated, 1775 (rats)
**Lysophosphatidic acid,** ovarian cancer, angiogenesis, and vascular endothelial growth factor, 734 (editorial), 762

**Magnetic resonance imaging,** breast cancer, mammography versus, 1095, 1754 (correspondence)
**Mammography**
ages 40–49, 1572 (correspondence)
breast cancer, risk factors and screening patterns, 1811
breast density, raloxifene and estrogen and, 51
clinical breast examination versus, 151 (correspondence)
magnetic resonance imaging versus, 1095, 1754 (correspondence)
**Manganese superoxide dismutase,** lung cancer, risk and alanine-to-valine polymorphism, 1818
**Marimastat,** 181
**Mastectomy**
adjuvant tamoxifen and, 456
breast-conserving therapy versus, cost comparison, 447
prophylactic, 1586 (editorial), 1633
risk-reduction, 1297 (review)
**Matrix metalloproteinase (MMP) inhibitors,** 178 (review)
clinical development, 187
**Mayo Lung Project**, 320 (correspondence)
**MEK inhibitors,** blocking oncogenic Ras signaling for cancer therapy, 1070
**Melanoma**
breast and pancreas carcinomas and, in CDKN2A mutation-positive melanoma families, 323 (correspondence)
CC chemokine receptor-7 and, 1588 (editorial), 1638 (mice)

incidence, 678, 831
mortality, 1973–1998, 831
**Melphalan resistance**, homologous recombinational repair, 1473
**Menopause,** breast cancer, serum hormones and alcohol association, 710
**Mesentery cancer,** 1973–1998, 836
**Metabolism,** lung carcinogen, tobacco metabolites in environmental smoke, nonsmoking women, 378, 1574 (correspondence)
**Metastasis**
bone cancer, methodology for treatment evaluation, 534
breast cancer
HER-2/neu amplification and expression, and herceptin response, 1120 (editorial), 1141
parathyroid hormone and, 234
matrix metalloproteinase inhibitors and, 178
melanoma, CC chemokine receptor-7 and, 1588 (editorial), 1638 (mice)
pheochromocytoma, radiofrequency ablation, 648 (correspondence)
prostate cancer survival, African Americans, 219, 1174 (correspondence)
**Methylation**
lung cancer, and retinoic acid receptor-β gene, 66 (correspondence)
nonpromoter CpG islands susceptibility, 1465
**Microarray analysis**
ovarian cancer, 1458
subcellular micromolecular pharmacotherapy using computer-assisted microarray analysis, 1350 (correspondence)
**Microsatellites**
bladder cancer detection, Chinese, 45
colorectal cancer, origin in hyperplastic polyps and serrated adenomas, 1282 (editorial), 1307
**Milk,** colorectal cancer, milk intake, circulating levels of insulin-like growth factor-I, and risk in men, 1330
**Mismatch repair,** colorectal cancer, DMH-induced, 1534 (mice)
**Mitomycin C,** bladder cancer, 572 (editorial), 597, 1574 (correspondence)
**Modeling,** side effects of cancer treatment and, 813
**Molecular chaperones,** heat shock response in oncogenesis and cell death, 239 (correspondence)
**Molecular targeting,** lung cancer, *N*-(4-hydroxyphenyl)retinamide, and hTERT in smokers' lungs, 1190 (editorial), 1257
**Monocytes,** promotion of monocytic differentiation, carnosic acid and, 1224
**Mortality**
1973–1998, 824, 1656 (correspondence)
lung cancer, 277, 320 (correspondence)
nasopharyngeal radium irradiation, cancer mortality after irradiation in childhood, Netherlands, 1021, 1661 (*erratum*)
prostate cancer, 397 (correspondence), 876 (correspondence)
**M-ras,** blocking oncogenic Ras signaling for cancer therapy, 1066
**msh2,** lymphoma, DMH-induced, 1534 (mice)
**Multidrug resistance,** ceramide metabolism, 351
**Multiple melanoma**, breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families, 323 (correspondence)
**Multiple myeloma**, familial, 1479
**Mutation**
liver cancer, oxidative stress and p53 mutations in the carcinogenesis or iron overload-associated hepatocellular carcinoma, 1652
population-based studies, genetic cancer risk, 1188 (editorial), 1215
Ras, blocking oncogenic signaling for cancer therapy, 1064

**NAD(P)H:quinone oxidoreductase 1,** skin cancer, and DMBA sensitivity, 1166 (mice)
**Nasopharyngeal radium irradiation,** cancer mortality after irradiation in childhood, Netherlands, 1021, 1661 (*erratum*)
**National Surgical Adjuvant Breast and Bowel Project**
breast cancer
ER-negative, adjuvant therapy, 80 (editorial), 112, 1420 (correspondence), 1661 *(erratum)*
tamoxifen, and depression, 1615
tamoxifen, five versus ten years, 662 (editorial), 684
Project B-14, trial update, tamoxifen, and breast cancer, lymph node-negative, 1493 (correspondence)
**Nausea,** behavioral intervention to control side effects of cancer treatment, 813
**Netherlands,** nasopharyngeal radium irradiation, cancer mortality after irradiation in childhood, 1021, 1661 (*erratum*)
**Neutropenia, febrile,** granulocyte colony-stimulating factor, 31
**News media,** cancer risk, and clinical oncology practice, 1656 (correspondence)
**Nicotine,** machine-smoked cigarettes versus intake in smokers, 134
**Night,** breast cancer, light at night, night-shift work, and risk, 1513 (editorial), 1557, 1563
**Nipple aspiration**, 1762 (editorial), 1791
ductal lavage versus, to detect cellular atypia, 1624
**Nitric oxide,** chemosensitivity in cancer cells, 1879
***N*-Nitrosomethylbenzylamine,** esophageal cancer, effects of dietary *N*-(4-hydroxyphenyl)retinamide on *N*-nitrosomethylbenzylamine metabolism and esophageal tumorigenesis, 990 (rats)
**Non-Hodgkin's lymphoma**
autologous bone marrow transplantation, 4 (editorial)
high-dose chemotherapy, 22
incidence and mortality, 1973–1998, 830
**Nonpeptidic MMP inhibitors,** 178
**Nordic countries,** cancer in ataxia-telangiectasia heterozygotes, 84 (editorial), 121
**No-touch technique,** guidelines 2000 for colon and rectal cancer surgery, 589

**Oligonucleotide 4625,** breast cancer, bcl-2 and bcl-xL inhibition, 463
**Oltipraz,** breast cancer prevention, 39
**Omentum cancer**, 1973–1998, 836
**Oncogenesis,** heat shock response and molecular chaperones in cell death and, 239 (correspondence)
**Oophorectomy,** guidelines 2000 for colon and rectal cancer surgery, 590
**ORF65,** HHV8, intrafamilial transmission, 154 (correspondence)
**Organochlorines,** breast cancer and, 768
**Orhopedic implants,** hip implant and risk, Sweden, 1405
**Orolaryngeal cancer,** tobacco carcinogen-detoxifying enzyme UGT1A7 and risk, 1411
**Osteoporosis**, estrogen receptor modulation, 1449 (review)
**Ovarian cancer**
angiogenesis, lysophosphatidic acid, and vascular endothelial growth factor, 734 (editorial), 762
biomarkers, 1437 (editorial), 1458
epidermal growth factor receptor signaling, and invasive phenotype, 1375
exercise and, 942
multiple births and, 319 (correspondence)
population-based studies, genetic cancer risk, 1188 (editorial), 1215
retinoids for prevention, 486 (editorial), 516
telomerase suppression by chromosome 6 in a HPV16 cell line, 865
**Ovarian tumors,** low malignant potential, molecular evidence, 1122 (editorial), 1147

**Oxidative stress,** liver cancer, oxidative stress and p53 mutations in the carcinogenesis of iron overload-associated hepatocellular carcinoma, 1652

**p53**
astrocytoma and glioblastoma, prognosis, 1246
breast cancer, mutations, 666 (editorial), 700
liver cancer, oxidative stress and p53 mutations in the carcinogenesis or iron overload-associated hepatocellular carcinoma, 1652
responsiveness, and individual variation, 82 (editorial), 128
**Paclitaxel,** breast cancer, pneumonitis, radiotherapy and, 1806
**Pain,** behavioral intervention to control side effects of cancer treatment, 814
**Pancreas cancer**
familial risk, 640
*Helicobacter pylori,* 937
multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families, 323 (correspondence)
**Parathyroid hormone,** breast cancer, bone metastasis, 234
**Patient characteristics,** colorectal cancer, influence on treatment and outcomes, 501 (review)
**Peptide growth factors,** prostate cancer, and androgen receptor signaling, 1690
**Peptidomimetic MMP inhibitors,** 178
**Perforation, inadvertent,** guidelines 2000 for colon and rectal cancer surgery, 589
**Peritoneal tumors,** low malignant potential, molecular evidence, 1122 (editorial), 1147
**Peritoneum cancer**, incidence and mortality, 1973–1998, 836
**Pharmacotherapy,** subcellular micromolecular pharmacotherapy using computer-assisted microarray analysis, 1350 (correspondence)
**Phenotype**
ovarian cancer
epidermal growth factor receptor signaling, and invasive phenotype, 1375
retinoids for prevention, 486 (editorial), 516
**Pheochromocytoma**, metastatic, radiofrequency ablation, 648 (correspondence)
**Phosphoinositide 3′-kinase,** blocking oncogenic Ras signaling for cancer therapy, 1062
**Physicians,** colorectal cancer, patient and provider characteristics, influence on treatment and outcomes, 505
**Placenta,** breast cancer, risk and, 1119 (editorial), 1133
**Plasma insulin-like growth factor-I,** prostate cancer risk and, 649 (correspondence)
**Plasmids,** lymphoma, B7-1 immunogene therapy, 1541 (mice)
**Plasminogen activator inhibitor type 1,** breast cancer, lymph node-negative, 913
**Pneumonitis,** breast cancer, radiotherapy and paclitaxel and, 1806
**Polyamine,** prostate, levels, 57
**Polychlorinated biphenyls,** breast cancer and, 768
**Polycyclic aromatic hydrocarbons,** maternal genetic effects on neonatal susceptibility to oxidative damage from environmental tobacco smoke, 645
**Polyps, hyperplastic,** colorectal cancer origin, 1282 (editorial), 1307
**Population-based studies,** role in assessing genetic cancer risk, 1188 (editorial), 1215
**Positron emission tomography**, breast cancer, staging with 2-fluoro-2-deoxy-D-glucose, 630
**Pregnancy,** breast cancer, risk and, 1119 (editorial), 1133
**Prevention**
diet and, 790 (correspondence)
esophageal cancer, prevention by zinc replacement, 1525 (rats)
ovarian cancer, retinoids for prevention, 486 (editorial), 516
**Probasin promoter $ARR_2PB$,** prostate cancer, androgen-dependent apoptosis, 1314
**Prognosis**
astrocytoma and glioblastoma, 1246
breast cancer, ER-negative, 80 (editorial), 112, 1420 (correspondence), 1661 *(erratum)*
tumor hypoxia and, 272
**Prostate,** α-difluoromethylornithine and polyamine levels, 57
**Prostate cancer**
African Americans, survival, 219, 1174 (correspondence)
androgen receptor signaling, 1687 (review)
Av-$ARR_2$PB-Bax-induced, androgen-dependent apoptosis, 1314
bcl-2 expression, angiogenic potential, 208
canarypox viruses, activation of immunoregulatory cells with, 998 (mice)
cause of death, 397 (correspondence), 1822
dexamethasone and, 1739
diet, oxidative DNA damage in patients consuming tomato sauce-based entrees, 24-7
fibroblast growth factor receptor signaling, and cell survival, 1783 (cells)
GSTP1 methylation, 1747
incidence, 829, 876 (correspondence), 1109 (correspondence)
insulin and leptin and, China, 783
mortality, 829, 876 (correspondence), 1109 (correspondence)
prostatectomy versus radiotherapy, 401 (correspondence)
race and ethnicity, 388
risk, 649 (correspondence)
plasma insulin-like growth factor-I, and insulin-like growth factor-binding proteins, 649 (correspondence)
screening
Finland, 552
Netherlands, 1153
socioeconomic status and incidence, 704
treatment, and nonclinical factors, 1864
**Prostatectomy**, radiotherapy versus, 401 (correspondence)
**Prostatin**, 1458
**Protein prenylation,** blocking oncogenic Ras signaling for cancer therapy, 1062 (review)
**Proteome**, tumor hypoxia and, 268
**Proteomics,** ovarian cancer, 1437 (editorial)
**Provider characteristics,** colorectal cancer, influence on treatment and outcomes, 501 (review)
**PTEN,** astrocytoma and glioblastoma, prognosis, 1246
**Public health,** cancer in ataxia-telangiectasia heterozygotes, 84 (editorial), 121

**Rac,** blocking oncogenic Ras signaling for cancer therapy, 1066
**Race,** *see* Ethnicity
**Radial margin,** guidelines 2000 for colon and rectal cancer surgery, 585
**Radiation**
γ-, glioma, and predisposition, 1512 (editorial), 1553
ionizing, epidermal growth factor receptor and, 890 (editorial), 921
UV, p53 responsiveness, 82 (editorial), 128
**Radiofrequency ablation,** pheochromocytoma, metastatic, 648 (correspondence)
**Radiosensitization,** epidermal growth factor receptor and, 890 (editorial), 921
**Radiotherapy**
breast cancer
relationship of distance from a facility and initial treatment, 1344
pneumonitis, paclitaxel and, 1806

ceramide metabolism, 351
p53 responsiveness, 82 (editorial), 128
prostate cancer, versus prostatectomy, 401 (correspondence)
**Raf-1,** blocking oncogenic Ras signaling for cancer therapy, 1065
**Raf kinase inhibitors,** blocking oncogenic Ras signaling for cancer therapy, 1070
**Raloxifene**
breast cancer and, 1453
breast density, 51
**Ras,** blocking oncogenic signaling for cancer therapy, 1062 (review)
**RASSFIA,** lung and breast cancers, epigenetic inactivation of, 664 (editorial), 691
**RBP1L1,** retinoblastoma, binding protein-related gene encoding an antigenic epitope, 1159
**Rectal cancer,** *see* Colorectal cancer
**Rectum,** guidelines 2000 for colon and rectal cancer surgery, 587
**Recurrence,** statistics of recurrent events, 488 (editorial)
**Relaxation training,** side effects of cancer treatment and, 812
**Reoviruses,** gliomas, oncolytic agent, 889 (editorial), 903
**Resection,** guidelines 2000 for colon and rectal cancer surgery, 583
**Retinoblastoma**
p16 gene pathway, cyclin-dependent kinase inhibitors and, 415 (editorial)
RBP1L1, binding protein-related gene encoding an antigenic epitope, 1159
**Retinoic acid**
all-*trans*-, promotion of monocytic differentiation, carnosic acid versus, 1224
breast cancer prevention, 39
ovarian cancer, prevention, 486 (editorial), 516
**Retroviral endostatin gene transfer,** gene therapy for anti-angiogenesis, 965 (editorial), 1014 (mice)
**Retroviruses,** lung cancer, animal model and, 1603 (review) (sheep)
**Rho,** blocking oncogenic Ras signaling for cancer therapy, 1066
**Risk assessment**
bladder cancer
benzidine exposure, biomarkers and, 427, 1492 (correspondence)
gender, smoking, and, 538 cancer in men exposed to diethylstilbestrol *in utero,* 545
breast cancer
DCIS, and screening patterns, 1811
models for projecting, 334 (editorial), 358
placenta and, 1119 (editorial), 1133
cellular telephones, Denmark, 166 (editorial), 203, 877 (correspondence), 952 (correspondence)
colorectal cancer
fruit, vegetables, and dietary fiber, 525
HRT and recurrence, 1764 (editorial), 1799
communication, 398 (correspondence)
gender, smoking, and cancer, 1600
hip implant and, Sweden, 1405
population-based studies, role in assessing genetic cancer, 1188 (editorial), 1215

**Scottish Adjuvant Tamoxifen Trial,** breast cancer, mastectomy and adjuvant tamoxifen, 456
**Screening**
colonoscopy, cost-effectiveness, 480 (correspondence)
progress over a decade, 1676 (editorial), 1704
prostate cancer, Netherlands, 1153
ovarian cancer, 1437 (editorial), 1458
*see also* Mammography
**Second malignant neoplasms,** childhood cancers, five-year survivors, 618
**Second primary tumors,** prevention in non-small-cell lung cancer, 605
**Serine–threonine kinase MEKK1R-ras,** blocking oncogenic Ras signaling for cancer therapy, 1066
**Sex,** *see* Gender
**Sheep,** lung cancer, animal model, 1603 (review) (sheep)
**Side effects,** behavioral intervention, 810 (review)
**Skin cancer**, DMBA sensitivity, and NQO1, 1166 (mice)
**Small intestine cancer,** incidence and mortality, 1973–1998, 835
**Smoking**
breast cancer, mortality and passive smoking, 717 (correspondence)
bladder cancer, gender, smoking, and risk, 538
gender, and cancer risk assessment, 1600
Hutchinson Prevention Project, 1267 (correspondence)
*N*-(4-hydroxyphenyl)retinamide, and hTERT, 1190 (editorial), 1257
lung cancer
chemoprevention and biomarkers, 1042 (editorial), 1081
tobacco metabolites in environmental smoke, nonsmoking women, 378, 1574 (correspondence)
maternal genetic effects on neonatal susceptibility to oxidative damage from environmental tobacco smoke, 645
nicotine, machine-smoked cigarettes versus intake in smokers, 134
orolaryngeal cancer, tobacco carcinogen-detoxifying enzyme UGT1A7 and risk, 1411
**Sociodemographics,** prostate cancer treatment and, 1864
**Socioeconomics**
colorectal cancer, patient and provider characteristics, influence on treatment and outcomes, 511
prostate cancer, socioeconomic status and incidence, 704
**Soft tissue cancers,** incidence and mortality, 1973-1998, 834
**Solid tumors**, tumor hypoxia and, 267
**Somatic mutation,** leukemia/lymphoma, HTLV1 provirus during clonal expansion, 367
**Sonic hedgehog gene,** adenovirus-mediated expression of Shh gene on hair regrowth after chemotherapy-induced alopecia, 1858 (mice)
**Statistics,** recurrent events, 488 (editorial)
**Stem cell transplant,** number of, 949 (correspondence)
**Stomach cancer,** *Helicobacter pylori,* China, 226
**Stool,** colorectal cancer, DNA-based detection, 798 (editorial), 858
**Suppressor genes,** lung and breast cancers, epigenetic inactivation of RASSFIA, 664 (editorial), 691
**Surgeons,** colorectal cancer, patient and provider characteristics, influence on treatment and outcomes, 502
**Surgery**
colon cancer, age and adjuvant chemotherapy after surgery and, 850
documentation, guidelines 2000 for colon and rectal cancer surgery, 591
guidelines 2000 for colon and rectal cancer surgery, 583
**Surivin,** lymphoma, B7-1 immunogene therapy, 1541 (mice)
**Sweden,** hip implant and risk, 1405
**Synovial sarcoma,** novel fusion gene, SYT-SSX4, 1347 (correspondence)
**Systematic desensitization,** side effects of cancer treatment and, 812

**Tamoxifen, and breast cancer**
contralateral cancer risk, and, 963 (editorial), 1008, 1753 (correspondence)
depression and, 1615
five versus ten years, 662 (editorial), 684
lymph node-negative and, 1493 (correspondence)
mastectomy and adjuvant tamoxifen, 456
prevention, 16, 39 , 1451
**Taxanes,** colon and breast cancer, drug resistance and P-glycoprotein modulation, 1234

**T-cell immunity,** peptide-induced, HTLV-I–associated lymphomas, 1775 (rats)
**Telomerase**
*cis*-activation of hTERT by the hepatitis B virus genome, 1171
ovarian cancer, suppression by chromosome 6 in a HPV16 cell line, 865
**Testicular cancer,** extragonadal germ cell tumors and, 1733
**Tetracycline derivatives**, 186
**Therapy,** MMPs and, 180
**Thyroid cancer,** incidence and mortality, 1973–1998, 834
**TNM staging,** guidelines 2000 for colon and rectal cancer surgery, 584
**Tobacco,** *see* Smoking
**Tomato sauce,** prostate cancer, oxidative DNA damage in patients consuming tomato sauce-based entrees, 1872
**TP53,** colorectal cancer, detection, 798 (editorial), 858
**Transcription**
tumors, transcriptional response to hypoxia, 1337
ovarian cancer, transcriptional profiling, 1437 (editorial),1458
**Transforming growth factor-β signaling,** role in cancer, 555 (correspondence)
**Transfusion,** cancer therapy–induced anemia, versus epoetin, 1204 (review)
**Trastuzumab,** *see* Herceptin
**Treatment evaluation,** bone metastasis, methodology for treatment evaluation, 534
**Treatment resistance**, tumor hypoxia and, 271
**β-Tubulin gene,** lung cancer, non-small-cell and, 1832 (editorial), 1886
**Tumor growth, development, and progression**, 238 (correspondence), 876 (correspondence), 1577 *(erratum)*
angiogenic therapy, 382 (mice)
cyclin-dependent kinase 4, small molecule inhibitor, 436
MMPs and, 180
tumor hypoxia and, 270
**Tumorigenesis**
esophageal cancer, effects of dietary *N*-(4-hydroxyphenyl) retinamide on *N*-nitrosomethylbenzylamine metabolism and esophageal tumorigenesis, 990 (rats)
lung cancer modifiers, 1484 (mice)
**Tumors**
hypoxia, 266 (review), 270
propagation, tumor hypoxia and, 268
transcriptional response to hypoxia, 1337
**Twin studies,** breast cancer, *in utero* estrogen exposure, 60

**UGT1A7,** orolaryngeal cancer, tobacco carcinogen-detoxifying enzyme UGT1A7 and risk, 1411
**United Kingdom,** prostate cancer, incidence and mortality, U.S. and U.K., 1109 (correspondence)
**Urinary markers,** bladder cancer, 413 (editorial)
**Urokinase-type plasminogen activator,** breast cancer, lymph node-negative, 913

**Vaccines**
HPV16 L1 VLP, 284
T-cell immunity, peptide-induced, HTLV-I–associated lymphomas, 1775 (rats)
**Vascular endothelial growth factor,** ovarian cancer, angiogenesis, lysophosphatidic acid, and 734 (editorial), 762
**Vegetables**
colorectal cancer risk, 525
prostate cancer, tomato sauce, oxidative DNA damage and, 1872
**Viruses**
adenovirus-mediated expression of Sonic hedgehog gene on hair regrowth after chemotherapy-induced alopecia, 1858 (mice)
EBV
breast cancer and, 148, 560 (correspondence)
interleukin-15 and, 1724
HBV
*cis*-activation of hTERT by the hepatitis B virus genome, 1171
liver cancer, hormonal markers and, 1644
HHP
anal cancer, in women, 843
cervical cancer and, 252 (editorial), 315, 1349 (correspondence)
HPV16
atypical squamous cells, 293, 950 (correspondence)
cervical cancer, variants in Asian Americans, 1325
cervical microvascular endothelial cells, activation by HPV16-E7 oncoprotein, 1843
L1 VLP vaccine, 284
telomerase suppression by chromosome 6, 865
HHV 8
intrafamilial transmission, 154 (correspondence)
prevalence, young adults, Denmark, 1569
HPV, Kaposi's sarcoma-associated, seroepidemiology and molecular epidemiology among Jews in Israel, 194
HTLV-1
-associated lymphomas, rat model, 1775 (rats)
proviruses, mutations during *in vivo* clonal expansion, 336 (editorial), 367
reoviruses, gliomas, oncolytic agent, 889 (editorial), 903
retroviruses
endostatin gene transfer, gene therapy for antiangiogenesis, 965 (editorial), 1014 (mice)
lung cancer, animal model and, 1603 (review) (sheep)
**Vomiting,** behavioral intervention to control side effects of cancer treatment, 813
**Vulva cancer,** incidence and mortality, 1973–1998, 835

**Wilms tumor,** insulin-like growth factor-II gene and, 1698

**Young adults,** HHV8 prevalence, Denmark, 1569

**Zinc,** esophageal cancer, prevention by zinc replacement, 1525 (rats)